[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 166
1. Malhan P, Husain N, Bhalla S, Gupta RK, Husain M: Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma. Indian J Pathol Microbiol; 2010 Jan-Mar;53(1):20-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferating cell nuclear antigen, p53 and micro vessel density: Grade II vs. Grade III astrocytoma.
  • Histological classification and grading are prime procedures in the management of patients with astrocytoma, providing vital data for therapeutic decision making and prognostication.
  • However, it has limitations in assessing biological tumor behavior.
  • This study was carried out to compare proliferative indices using proliferating cell nuclear antigen (PCNA), extent of p53 expression and micro vessel morphometric parameters in patients with low grade and anaplastic astrocytoma.
  • Twenty-five patients, each of grade II and grade III astrocytoma were evaluated using monoclonal antibodies to PCNA, p53 protein and factor VIII related antigen.
  • Patients with grade III astrocytoma had higher PCNA and p53 labeling indices as compared with grade II astrocytoma (29.14 plus/minus 9.87% vs. 16.84 plus/minus 6.57%, p 0.001; 18.18 plus/minus 6.14% vs. 6.14 plus/minus 7.23%, p 0.001, respectively).
  • Micro vessel percentage area of patients with grade III astrocytoma was also (4.26 plus/minus 3.70 vs. 1.05 plus/minus 0.56, p 0.001), higher along with other micro vessel morphometric parameters.
  • Discordance between histology and one or more IHC parameters was seen in 5/25 (20%) of patients with grade III astrocytoma and 9/25 (36%) of patients with grade II disease.
  • Increased proliferative fraction, genetic alterations and neovascularization mark biological aggressiveness in astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / pathology. Neovascularization, Pathologic. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Antibodies, Monoclonal. Biometry / methods. Child. Child, Preschool. Humans. Immunohistochemistry / methods. Microscopy / methods. Middle Aged. Severity of Illness Index. Statistics as Topic. Young Adult

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090216.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


2. Nagy M, Schulz-Ertner D, Bischof M, Welzel T, Hof H, Debus J, Combs SE: Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas. Tumori; 2009 May-Jun;95(3):317-24
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas.
  • PURPOSE: Patients with anaplastic gliomas have a more favorable overall survival than patients with glioblastomas.
  • In most analyses, WHO grade III and 1V tumors are not analyzed separately.
  • The present analysis reports outcome after postoperative radiotherapy in patients with WHO grade III gliomas.
  • PATIENTS AND METHODS: Between January 1988 and January 2007, 127 patients with WHO grade III tumors were treated with radiotherapy; the histological classification was pure astrocytoma in 104 patients, oligoastrocytoma in 12 and pure oligodendroglioma in 11 patients.
  • Median overall survival was 7 months for patients with anaplastic astrocytomas, 44 months for patients with mixed tumors, and 47 months for those with pure oligodendrogliomas.
  • CONCLUSION: Patients with WHO grade III anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas show favorable overall survival after postoperative radiotherapy compared with glioblastoma patients and should therefore be analyzed separately.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radiotherapy. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Middle Aged. Oligodendroglioma / pathology. Oligodendroglioma / radiotherapy. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688970.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Anselmo NP, Rey JA, Almeida LO, Custódio AC, Almeida JR, Clara CA, Santos MJ, Casartelli C: Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma. Genet Mol Res; 2009;8(4):1257-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concurrent sequence variation of TP53 and TP73 genes in anaplastic astrocytoma.
  • Disruption or loss of tumor suppressor gene TP53 is implicated in the development or progression of almost all different types of human malignancies.
  • Using PCR-SSCP and gene sequencing, we analyzed the TP53 and TP73 genes in a case of a grade III anaplastic astrocytoma that progressed to glioblastoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA-Binding Proteins / genetics. Nuclear Proteins / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Base Sequence. DNA Primers. Humans. Male. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19876867.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  •  go-up   go-down


Advertisement
4. Henriksson R, Malmström A, Bergström P, Bergh G, Trojanowski T, Andreasson L, Blomquist E, Jonsborg S, Edekling T, Salander P, Brännström T, Bergenheim AT: High-grade astrocytoma treated concomitantly with estramustine and radiotherapy. J Neurooncol; 2006 Jul;78(3):321-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade astrocytoma treated concomitantly with estramustine and radiotherapy.
  • The present study is an open randomized clinical trial comparing estramustine phosphate (Estracyt) in addition to radiotherapy with radiotherapy alone as first line treatment of astrocytoma grade III and IV.
  • For astrocytoma grade III the median survival time was 10.6 (1.3-92.7) months for the radiotherapy only group and 17.3 (0.4-96.9+) months for the estramustine + radiotherapy group.
  • In grade IV the corresponding median survival time was 12.3 (2.1-89.2) and 10.3 (0.3-91.7+) months, respectively.
  • Median time to progress for radiotherapy only and radiotherapy and estramustin group in grade III tumours was 6.5 and 10.1 months, respectively.
  • In grade IV tumours the corresponding figures were 5.1 and 3.3 months, respectively.
  • Although there was a tendency for improved survival in grade III, no statistical significant differences were found between the treatment groups.
  • In conclusion, this first randomized study did not demonstrate any significant improvement of using estramustine in addition to conventional radiotherapy, however, a trend for a positive response for the estramustine group was found in patients with grade III glioma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Estramustine / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Quality of Life. Radiotherapy Dosage. Severity of Illness Index. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1713-6 [2697186.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):360-6 [8832674.001]
  • [Cites] Br J Cancer. 1988 Sep;58(3):326-9 [3052561.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1394-400 [1873791.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):640-6 [10931464.001]
  • [Cites] Prostate. 1989;14(1):27-43 [2648345.001]
  • [Cites] Anticancer Res. 1990 May-Jun;10(3):693-6 [2369085.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):215-20 [15072470.001]
  • [Cites] J Clin Oncol. 2001 Feb 15;19(4):1111-7 [11181676.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):962-4 [1709687.001]
  • [Cites] Br J Cancer. 1993 Feb;67(2):358-61 [8431366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jun 1;44(3):535-43 [10348282.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):142-8 [10389990.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1254-9 [10715295.001]
  • [Cites] J Neurooncol. 1994;22(2):111-26 [7745464.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):717-20 [7710934.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):87-91 [9516956.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):555-7 [8005815.001]
  • [Cites] Clin Pharmacokinet. 1998 Feb;34(2):163-72 [9515186.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1415-7 [8137240.001]
  • [Cites] Neurosurgery. 1993 Mar;32(3):422-30; discussion 430-1 [8384327.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2079-84 [9748122.001]
  • [Cites] J Neurooncol. 1995;23(3):191-200 [7673981.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4974-9 [8069865.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurol. 1975 Jul 2;209(3):217-24 [51062.001]
  • (PMID = 16598426.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 35LT29625A / Estramustine
  •  go-up   go-down


5. Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim IH, Jung HW: Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer; 2009;9:450
Hazardous Substances Data Bank. VINDESINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy.
  • BACKGROUND: We evaluated the hierarchical risk groups for the estimated survival of WHO grade III glioma patients using recursive partitioning analysis (RPA).
  • To our knowledge, this is the first study to address the results of RPA specifically for WHO grade III gliomas.
  • METHODS: A total of 133 patients with anaplastic astrocytoma (AA, n = 56), anaplastic oligodendroglioma (AO, n = 67), or anaplastic oligoastrocytoma (AOA, n = 10) were included in the study.
  • CONCLUSION: The present study shows that RPA grouping with clinical prognostic factors can successfully predict the survival of patients with WHO grade III glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Classification / methods. Glioma / diagnosis. Glioma / therapy. Neoplasm Staging / methods. Radiotherapy
  • [MeSH-minor] Adult. Aged. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Humans. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Vindesine / therapeutic use. World Health Organization

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3389-95 [10550132.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1169-76 [18938045.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):321-4 [2154418.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4002-6 [8508366.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Neurology. 1994 Aug;44(8):1479-83 [8058153.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1018-34; discussion 1034-5 [7885546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 [9128946.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):193-6 [16611661.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] J Neurooncol. 2007 Feb;81(3):295-303 [17001519.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):575-81 [17432706.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Jul;63(1):72-80 [17478095.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1089-109, ix-x [17964027.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):307-16 [18532929.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):509-18 [11208845.001]
  • (PMID = 20017960.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; RSA8KO39WH / Vindesine; PCV regimen
  • [Other-IDs] NLM/ PMC2806410
  •  go-up   go-down


6. Mahzouni P, Mohammadizadeh F, Mougouei K, Moghaddam NA, Chehrei A, Mesbah A: Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):605-10
Hazardous Substances Data Bank. FORMALDEHYDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels.
  • BACKGROUND: Astrocytic brain tumors are the most common primary central nervous system tumors, which are classified into four grades.
  • One of the most important pathologic criteria for the diagnosis of higher-grade astrocytomas (especially glioblastoma multiforme) is microvessel proliferation, particularly in the form of glomeruloid complex.
  • Because tumor angiogenesis is a necessary factor for growth and invasiveness of malignancies, microvessel density (MVD) and intensity of angiogenesis may be used to determine the grade of astrocytomas and plan therapy accordingly.
  • We have planned this study to evaluate the relationship between vwf expression in microvessels and different grades of astrocytoma.
  • MATERIALS AND METHODS: Sixty-four formalin-fixed and paraffin-embedded blocks of surgical specimens with diagnosis of astrocytoma (grades I to IV, each of them 16 blocks) were selected in a simple-nonrandom sampling.
  • Scores 0 and 1 of microvessel staining intensity were not observed in any grades studied, but severe staining intensity (score 3) was observed in 18.8%, 37.5%, 56.3%, and 87.5% of grades I, II, III, and IV astrocytomas, respectively.
  • "Vwf vessel index" (MVD staining intensity of microvessels) was 23.84, 25.62, 31.62, and 62.43 in grades I, II, III, and IV astrocytomas, respectively.
  • The intensity of microvessel stain increases in parallel with increasing tumor grade.
  • Regarding "microvessel density" and "vwf vessel index," the difference is predominantly between grade IV and all other grades.
  • However, there is no other statistically meaningful difference between grades I, II and III.
  • [MeSH-major] Astrocytoma / pathology. Microvessels / pathology. Neovascularization, Pathologic. Severity of Illness Index. von Willebrand Factor / analysis
  • [MeSH-minor] Adult. Child. Female. Formaldehyde. Humans. Immunohistochemistry / methods. Male. Microscopy. Middle Aged. Paraffin Embedding. Pathology / methods. Statistics as Topic. Tissue Fixation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045378.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / von Willebrand Factor; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


7. Arslantas A, Artan S, Oner U, Müslümanoglu MH, Ozdemir M, Durmaz R, Arslantas D, Vural M, Cosan E, Atasoy MA: Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas. Pathol Oncol Res; 2007;13(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.
  • To extend our understanding of potential stepwise genetic alterations that may underlie tumor progression from low-grade astrocytomas to glioblastomas, histopathologic and comparative genomic hybridization analyses were performed on tumor specimens from 68 primary lesions, including 40 glioblastomas, 10 anaplastic and 18 low-grade astrocytomas.
  • The number of aberrations per case increased towards the higher grade tumors (grade II: 1.66+/-1.49; grade III: 2.80+/-1.68; grade IV: 3.02+/-1.07; F=6.955, p=0.002).
  • A gain of 7/7q was common and the most frequently seen aberration in low-grade astrocytomas, whereas loss of 10q was the most frequently seen anomaly in anaplastic astrocytomas and glioblastomas.
  • Chromosome 10/10q deletion and combination of 1p, 19q and 17p deletions were specific to high-grade astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosome Deletion. Glioblastoma / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurol Belg. 2002 Jun;102(2):53-62 [12161900.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):375-86 [10433931.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1397-401 [8137236.001]
  • [Cites] Neurol Med Chir (Tokyo). 2003 Jan;43(1):12-8; discussion 19 [12568317.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Apr;61(4):321-8 [11939587.001]
  • [Cites] Mol Carcinog. 2003 Jan;36(1):6-14 [12503074.001]
  • [Cites] Hum Genet. 1993 Sep;92(2):169-74 [8370584.001]
  • [Cites] Front Biosci. 2003 May 01;8:e281-8 [12700122.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Nat Genet. 1997 Sep;17(1):32-9 [9288095.001]
  • [Cites] Anticancer Res. 1994 Mar-Apr;14(2A):577-9 [8017863.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jan;42(1):68-77 [15472895.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] Clin Neurol Neurosurg. 1997 May;99(2):117-23 [9213056.001]
  • [Cites] Neurosurg Rev. 2004 Jan;27(1):58-64 [12845540.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1203-18 [8203461.001]
  • [Cites] Oncogene. 1997 Jun 19;14(24):2927-33 [9205099.001]
  • [Cites] Cancer Lett. 1999 Jan 8;135(1):61-6 [10077222.001]
  • [Cites] Br J Cancer. 1996 Feb;73(4):424-8 [8595154.001]
  • [Cites] Int J Cancer. 1999 Apr 20;84(2):150-4 [10096247.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):1141-50 [12370766.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Hum Pathol. 2000 May;31(5):608-14 [10836301.001]
  • [Cites] Virchows Arch. 1995;427(2):113-8 [7582239.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6353-8 [7987828.001]
  • (PMID = 17387387.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


8. Jayawardena S, Sooriabalan D, Indulkar S, Kim HH, Matin A, Maini A: Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate. Am J Ther; 2006 Sep-Oct;13(5):458-9
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regression of grade III astrocytoma during the treatment of CML with imatinib mesylate.
  • The cells that demonstrate the greatest degree of anaplasia are used to determine the histologic grade of the tumor.
  • The mean age of survival are approximately 10 years from the time of diagnosis for pilocystic astrocytomas (World Health Organization grade I), more than 5 years for patients with low-grade diffuse astrocytomas (WHO grade II), 2 to 5 years for those with anaplastic astrocytomas (WHO grade III), and less than 1 year for patients with glioblastoma (WHO grade IV).
  • The treatment is a combination of surgery, radiation, and chemotherapy depending of the grade of astrocytoma.
  • We present a case of 31-year-old man with grade III astrocytoma with subsequent chronic myelogenous leukemia treated with imatinib mesylate as part of his chronic myelogenous leukemia treatment failing to show recurrence of the astrocytoma 10 years after standard treatment for astrocytoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Leukemia, Myeloid, Acute / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Combined Modality Therapy. Humans. Imatinib Mesylate. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988542.001).
  • [ISSN] 1075-2765
  • [Journal-full-title] American journal of therapeutics
  • [ISO-abbreviation] Am J Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


9. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C: Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol; 2009 Sep;118(3):401-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
  • Separation of pilocytic astrocytoma from diffuse astrocytomas frequently poses problems mostly related to small sample size.
  • Precise classification and grading are essential due to different therapeutic strategies prompted by diagnoses of pilocytic astrocytoma WHO grade I, diffuse astrocytomas WHO grade II or anaplastic astrocytoma WHO grade III.
  • IDH1 mutations are observed very frequently in adult astrocytomas and IDH2 mutations have been reported in some astrocytomas.
  • We examined a series of 120 astrocytomas including 70 pilocytic astrocytomas WHO grade I and 50 diffuse astrocytomas WHO grade II for both, BRAF-KIAA1549 fusion with a newly developed FISH assay and mutations in IDH1 and IDH2 by direct sequencing.
  • Astrocytomas WHO grade II exhibited IDH1 mutations in 38 cases (76%) but neither IDH2 mutations nor BRAF fusions.
  • Thus, combined molecular analysis of BRAF and IDH1 is a sensitive and highly specific approach to separate pilocytic astrocytoma from diffuse astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Isocitrate Dehydrogenase / genetics. Proto-Oncogene Proteins B-raf / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Tissue Array Analysis


10. Hales RK, Shokek O, Burger PC, Paynter NP, Chaichana KL, Quiñones-Hinojosa A, Jallo GI, Cohen KJ, Song DY, Carson BS, Wharam MD: Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis. J Neurooncol; 2010 Aug;99(1):65-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in pediatric high-grade astrocytoma: the importance of accurate pathologic diagnosis.
  • To characterize a population of pediatric high-grade astrocytoma (HGA) patients by confirming the proportion with a correct diagnosis, and determine prognostic factors for survival in a subset diagnosed with uniform pathologic criteria.
  • Log-rank analysis was used to compare survival by patient, tumor, and treatment factors.
  • At initial diagnosis, 27 patients were grade III (43%) and 36 grade IV (57%).
  • Pathologic misdiagnosis should be suspected in patients who are long term survivors of a pediatric high grade astrocytoma.
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Cohort Studies. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Multivariate Analysis. Prognosis. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Br J Cancer. 2004 Aug 2;91(3):425-9 [15266331.001]
  • [Cites] Pediatr Neurosurg. 1994;20(4):226-32 [8043460.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1246-53 [10715294.001]
  • [Cites] J Neurol. 2000 Jun;247(6):455-60 [10929275.001]
  • [Cites] Cancer J. 2003 Mar-Apr;9(2):107-12 [12784876.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2563-9 [16735709.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2267-76 [11980997.001]
  • [Cites] AJR Am J Roentgenol. 2001 Aug;177(2):449-54 [11461881.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):421-5 [10199329.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Neurosurg. 1978 Sep;49(3):333-43 [355604.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):14-25 [11554386.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2887 [10870076.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):197-207 [12816726.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2124-8 [11280776.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1651-6 [3621134.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):817-24 [15305415.001]
  • [Cites] Childs Nerv Syst. 2008 Apr;24(4):467-75 [17978821.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1238-44; discussion 1244-5 [12015841.001]
  • [Cites] Brain Pathol. 2000 Apr;10 (2):249-59 [10764044.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):29-38 [18082451.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8220-8 [15623597.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2131-7 [11066055.001]
  • [Cites] J Neurosurg. 2003 Sep;99(3):467-73 [12959431.001]
  • [Cites] Neuroradiology. 1980;19(2):59-66 [6245388.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Oct;5(10):1725-31 [231022.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11172-8 [17145861.001]
  • (PMID = 20043190.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Yue WY, Yu SH, Zhao SG, Chen ZP: Molecular markers relating to malignant progression in Grade II astrocytoma. J Neurosurg; 2009 Apr;110(4):709-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular markers relating to malignant progression in Grade II astrocytoma.
  • OBJECT: Astrocytoma may progress rapidly or remain stable for many years.
  • To clarify whether molecular characteristics could be prognostic factors, several cell cycling-associated molecular alterations in the diffuse astrocytoma have been investigated.
  • METHODS: Thirty-three patients in whom WHO Grade II astrocytoma had been initially diagnosed were assigned to 1 of 3 groups.
  • Group 1 consisted of 10 patients with malignant progression; the tumor had recurred within 5 years and histological analysis had confirmed that the tumor progressed to Grade III or IV.
  • Group 2 consisted of 10 patients in whom there was no malignant progression; the tumor recurred within 5 years, but histological analysis confirmed that the tumor remained at Grade II.
  • Expression of Ki 67, TP53, p27, and p21 was examined using immunohistochemical analysis for the tumor samples obtained during the first and second (in recurrent cases) surgeries.
  • [MeSH-major] Astrocytoma / chemistry. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Ki-67 Antigen / analysis. Proliferating Cell Nuclear Antigen / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adult. Base Sequence. Disease Progression. Female. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19025355.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 0 / Tumor Suppressor Protein p53; 0 / p27 antigen
  •  go-up   go-down


12. Krzyszkowski T, Dziedzic T, Czepko R, Szczudlik A: Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma. Neurol Res; 2008 Apr;30(3):294-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased levels of interleukin-10 and transforming growth factor-beta 2 in cerebrospinal fluid of patients with high grade astrocytoma.
  • It is unknown if production of these cytokines is limited to the site of tumor or these molecules are also released to cerebrospinal fluid and blood.
  • The goal of our study was to determine if patients with astrocytoma have increased levels of IL-10 and TGF-beta 2 in cerebrospinal fluid (CSF) and serum.
  • METHODS: CSF and serum samples were taken from 16 patients with astrocytoma of grade III or grade IV according to the WHO classification and from 28 age- and gender-matched controls (patients with normal pressure hydrocephalus or with lumbar disk herniation).
  • Patients with astrocytoma had decreased levels of IL-10 (0.9 +/- 1.2 versus 3.5 +/- 9.2 pg/ml, p=0.01) and TGF-beta 2 (0.0 +/- 0.0 versus 5.4 +/- 9.4 pg/ml, p=0.05) in CSF compared to controls.
  • Because serum IL-10 and TGF-beta 2 levels are similar in patients with astrocytoma and in controls, these cytokines are probably not directly involved in peripheral monocyte and T cell deactivation.
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / cerebrospinal fluid. Interleukin-10 / blood. Interleukin-10 / cerebrospinal fluid. Transforming Growth Factor beta2 / blood. Transforming Growth Factor beta2 / cerebrospinal fluid
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Hydrocephalus, Normal Pressure / blood. Hydrocephalus, Normal Pressure / cerebrospinal fluid. Intervertebral Disc Displacement / blood. Intervertebral Disc Displacement / cerebrospinal fluid. Lumbosacral Region. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848206.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Transforming Growth Factor beta2; 130068-27-8 / Interleukin-10
  •  go-up   go-down


13. Combs SE, Gutwein S, Thilmann C, Debus J, Schulz-Ertner D: Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT). Strahlenther Onkol; 2005 Dec;181(12):768-73
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reirradiation of recurrent WHO grade III astrocytomas using fractionated stereotactic radiotherapy (FSRT).
  • PURPOSE: To assess the effect of reirradiation in recurrent WHO grade III astrocytomas.
  • PATIENTS AND METHODS: From January 1995 to July 2003, 40 patients with grade III gliomas were treated with fractionated stereotactic reirradiation at the time point of recurrence.
  • No toxicities > CTC grade 2 developed.
  • CONCLUSION: Fractionated stereotactic radiotherapy is well tolerated and effective in patients with recurrent grade III astrocytomas.
  • [MeSH-major] Astrocytoma / mortality. Astrocytoma / surgery. Brain Neoplasms / mortality. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Radiosurgery / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Dose Fractionation. Female. Germany / epidemiology. Humans. Incidence. Male. Middle Aged. Prognosis. Risk Assessment / methods. Risk Factors. Severity of Illness Index. Survival Analysis. Survival Rate. Treatment Outcome. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16362786.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Chen J, Xia J, Zhou YC, Xia LM, Zhu WZ, Zou ML, Feng DY, Wang CY: [Correlation between magnetic resonance diffusion weighted imaging and cell density in astrocytoma]. Zhonghua Zhong Liu Za Zhi; 2005 May;27(5):309-11
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between magnetic resonance diffusion weighted imaging and cell density in astrocytoma].
  • OBJECTIVE: To evaluate the apparent diffusion coefficients (ADC) in magnetic resonance diffusion weighted imaging with echo-planar technique in depicting the tumor cellularity and grading of astrocytoma.
  • METHODS: Thirty-four astrocytoma patients including 18 male and 16 female with age from 10 to 73 years (mean 38.4 years) were examined by MRI and eventually proved by surgical resection and pathological examination.
  • Of them, 26 had low-grade (grade I, II) astrocytoma and 8 high-grade (grade III, IV) astrocytoma.
  • ADC value of astrocytoma was determined on magnetic resonance diffusion weighted images.
  • Cellularity of the astrocytoma was analyzed using Adobe Photoshop 7.0.1 software.
  • RESULTS: The mean ADC value (in units of 10(-4) mm(2)/s) of the high-grade astrocytomas (7.34 +/- 2.95) was significantly lower than that of the low-grade astrocytomas (13.76 +/- 3.31) (t = 4.91, P < 0.001).
  • The mean cellularity of the high-grade astrocytomas (19.81 +/- 9.73)% was significantly higher than that of the low-grade astrocytomas (4.74 +/- 2.96)% (t = 4.32, P = 0.003).
  • ADC value of the astrocytoma was significantly and negatively correlated with its cellularity (r = -0.535, P = 0.001).
  • CONCLUSION: ADC value of astrocytoma is significantly and negatively correlated with its cellularity.
  • Magnetic resonance diffusion weighted imaging may well be highly potential in predicting the degree of astrocytoma.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Diffusion Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Child. Female. Glioblastoma / diagnosis. Glioblastoma / pathology. Humans. Image Processing, Computer-Assisted. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996330.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Lu Z, Wang Y, Zhang Q, Zhang X, Wang S, Xie H, Li Y, Jiao B, Zhang J: Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma. Brain Res; 2006 Nov 6;1118(1):6-12
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between the functional polymorphism in the matrix metalloproteinase-7 promoter and susceptibility to adult astrocytoma.
  • To study the association between the A to G transition at the -181-bp position in the promoter of matrix metalloproteinase-7 gene (MMP-7-181A/G) and susceptibility to adult astrocytoma, the MMP-7-181A/G polymorphism was genotyped by PCR-RFLP analysis among 221 adult astrocytoma patients and 366 healthy controls in a population of northern China.
  • The result showed that the overall distribution of the MMP-7 genotypes among astrocytoma patients and healthy controls was significantly different (P<0.001).
  • Compared with the A/A genotype, the G/G genotype significantly increased the risk to the development of astrocytoma (age and gender adjusted OR=2.77, 95% CI=1.27-6.02), while the MMP-7 A/G genotype only marginally increased the risk of developing this cancer (age and gender adjusted OR=1.66, 95% CI=0.99-2.84).
  • Stratification analysis showed that the G/G genotype significantly increased the risk of astrocytoma only among male subjects (age adjusted OR=3.24, 95% CI=1.12-9.41) and individuals younger than 45 years (age and gender adjusted OR=3.16, 95% CI=1.09-9.16).
  • When stratified by histological grades, a significant higher risk for developing grade II astrocytoma was observed among individuals harboring the A/G genotype (age and gender adjusted OR=2.06, 95% CI=1.05-4.05), while an about 3-fold elevation of risk to develop grades II, III, and IV astrocytomas was observed among individuals with the G/G genotype.
  • The present result, for the first time, suggested that the MMP-7-181A/G polymorphism might be associated with the susceptibility to adult astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Matrix Metalloproteinase 7 / genetics. Polymorphism, Genetic / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / genetics. DNA Mutational Analysis. Female. Gene Frequency. Genetic Markers / genetics. Genetic Testing. Genotype. Humans. Male. Middle Aged. Sex Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956593.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; EC 3.4.24.23 / Matrix Metalloproteinase 7
  •  go-up   go-down


16. Jiang Z, Hu J, Li X, Jiang Y, Zhou W, Lu D: Expression analyses of 27 DNA repair genes in astrocytoma by TaqMan low-density array. Neurosci Lett; 2006 Dec 1;409(2):112-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analyses of 27 DNA repair genes in astrocytoma by TaqMan low-density array.
  • The mRNA expressions of 27 genes of the DNA repair system as well as their correlation with the clinical characteristics were studied in human astrocytoma.
  • We applied TaqMan low-density array to investigate the mRNA expressions of 27 DNA repair genes in 40 astrocytoma tissues (10 of grade II, 10 of grade III, and 20 of grade IV, according to the WHO Grading System).
  • And the normal brain tissues from 10 non-astrocytoma patients were collected as the control.
  • We found that the expression of the 13 genes were significantly (P<0.01) down-regulated in grade II, III, IV of astrocytoma compared to normal brain tissues, including ERCC1, ERCC2, ERCC3, ERCC4, MGMT, MLH1, MLH3, NTHL1, OGG1, RAD50, SMUG1, XRCC4 and XRCC5.
  • Meanwhile, we found that the expression of MSH2, MSH6, NUDT1 and XRCC3 were only significantly lower in grade II and III of astrocytoma, and the expression of MRE11A and MUS81 were only significantly lower in grade III and IV.
  • But the expression of MPG, MSH3, MUTHY and RAD51 were not changed in any grade of astrocytoma.
  • We suggest that TaqMan low-density array is an effective multivariate technique to examine the expression of DNA repair genes in astrocytomas, which can be applied to identify tumor-specific genes.
  • We also suggest that the down-regulation of some DNA repair genes may be associated with pathogenesis and poor prognosis of astrocytoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. DNA Repair / genetics. Gene Expression Regulation, Neoplastic / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. DNA, Complementary / biosynthesis. DNA, Complementary / genetics. Female. Gene Expression / physiology. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17034947.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / RNA, Messenger
  •  go-up   go-down


17. Keles GE, Chang EF, Lamborn KR, Tihan T, Chang CJ, Chang SM, Berger MS: Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J Neurosurg; 2006 Jul;105(1):34-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma.
  • OBJECT: To investigate the prognostic significance of the volumetrically assessed extent of resection on time to tumor progression (TTP), overall survival (OS), and tumor recurrence patterns, the authors retrospectively analyzed preoperative and postoperative tumor volumes in 102 adult patients from the time of the initial resection of a hemispheric anaplastic astrocytoma (AA).
  • METHODS: The quantification of tumor volumes was based on a previously described method involving computerized analysis of magnetic resonance (MR) images.
  • Analysis of contrast-enhancing tumor volumes on T1-weighted MR images was conducted for 67 patients who had contrast-enhancing tumors.
  • The presence or absence of preresection enhancement, actual volume of this enhancement, and the percentage of preoperative enhancement as it relates to the total T2 tumor volume did not have a statistically significant relationship to TTP or OS.
  • In addition to age, the volume of residual disease measured on T2-weighted MR images was the most significant predictor of TTP (p < 0.001), and residual contrast-enhancing tumor volume was the most significant predictor of OS (p = 0.003) on multivariate analysis.
  • In contrast to low-grade gliomas, there was no statistically significant relationship between the extent of resection and histological characteristics at the time of recurrence, that is, tumor Grade III compared with Grade IV.
  • CONCLUSIONS: Data from this retrospective analysis of a histologically uniform group of hemispheric AAs treated in the MR imaging era suggest that residual tumor volumes, as documented on postoperative imaging studies, may be a prognostic factor for TTP and OS for this patient population.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / surgery. Brain Neoplasms / pathology. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm, Residual. Predictive Value of Tests. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871879.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


18. Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ: Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology; 2006 Apr;26(2):99-106
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma.
  • Furthermore, 5-LOX expression increased and showed a granular pattern in high-grade (grade III/IV) astrocytoma.
  • [MeSH-major] Arachidonate 5-Lipoxygenase / biosynthesis. Astrocytoma / metabolism. Brain / metabolism. Brain Injuries / metabolism. Brain Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Neuroglia / metabolism. Neurons / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16708542.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase
  •  go-up   go-down


19. MacDonald TJ, Pollack IF, Okada H, Bhattacharya S, Lyons-Weiler J: Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis. Methods Mol Biol; 2007;377:203-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression-associated genes in astrocytoma identified by novel microarray gene expression data reanalysis.
  • Astrocytoma is graded as pilocytic (WHO grade I), diffuse (WHO grade II), anaplastic (WHO grade III), and glioblastoma multiforme (WHO grade IV).
  • The progression from low- to high-grade astrocytoma is associated with distinct molecular changes that vary with patient age, yet the prognosis of high-grade tumors in children and adults is equally dismal.
  • Whether specific gene expression changes are consistently associated with all high-grade astrocytomas, independent of patient age, is not known.
  • We identified nine genes consistently dysregulated in high-grade tumors, using four novel tests for identifying differentially expressed genes.
  • Four genes encoding ribosomal proteins (RPS2, RPS8, RPS18, RPL37A) were upregulated, and five genes (APOD, SORL1, SPOCK2, PRSS11, ID3) were downregulated in high-grade by all tests.
  • Expression results were validated using a third astrocytoma dataset.
  • APOD, the most differentially expressed gene, has been shown to inhibit tumor cell and vascular smooth muscle cell proliferation.
  • This suggests that dysregulation of APOD may be critical for malignant astrocytoma formation, and thus a possible novel universal target for therapeutic intervention.
  • Further investigation is needed to evaluate the role of APOD, as well as the other genes identified, in malignant astrocytoma development.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression. Oligonucleotide Array Sequence Analysis / methods
  • [MeSH-minor] Adult. Child. Chromosomes, Human. Cluster Analysis. Data Interpretation, Statistical. Disease Progression. Gene Expression Regulation, Neoplastic. Humans. Models, Genetic. Neoplasm Recurrence, Local. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634619.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 49
  •  go-up   go-down


20. Hildebrand J, Gorlia T, Kros JM, Afra D, Frenay M, Omuro A, Stupp R, Lacombe D, Allgeier A, van den Bent MJ, EORTC Brain Tumour Group investigators: Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882). Eur J Cancer; 2008 Jun;44(9):1210-6
Hazardous Substances Data Bank. Carmustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant dibromodulcitol and BCNU chemotherapy in anaplastic astrocytoma: results of a randomised European Organisation for Research and Treatment of Cancer phase III study (EORTC study 26882).
  • BACKGROUND: In a previous randomised EORTC study on adjuvant dibromodulcitol (DBD) and bichloroethylnitrosourea (BCNU) in adults with glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), a clinically significant trend towards a longer overall survival (OS) and a progression-free survival (PFS) was observed in the subgroup of AA.
  • METHODS: Continuation of the previous phase III trial for newly diagnosed AA according to the local pathologist.
  • Central pathology review of grade 3 tumours remains crucial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy
  • [MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Carmustine / adverse effects. Chemotherapy, Adjuvant. Female. Hematologic Diseases / chemically induced. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Mitolactol / administration & dosage. Mitolactol / adverse effects. Treatment Failure

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18248979.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA 11488
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] LJ2P1SIK8Y / Mitolactol; U68WG3173Y / Carmustine
  • [Investigator] Afra D; Maat B; Hildebrand J; de Wit O; Frenay F; Chatel M; Rivier I; Taphoorn M; Delattre JY; de Tribolet N; Stupp R; Punt J; Garfield J; Chinot O; van den Bent M; Lahrmann H; Cristo C; Mouchamps M; Haferkamp G; Bravo Marques J
  •  go-up   go-down


21. Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW: Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res; 2005 Jun 13;137(1-2):98-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas.
  • Polymorphisms in codon 72 of the p53 tumor suppressor gene have been associated with susceptibility to human cancer.
  • In this study, we scored 135 brain tumor samples (92 adult and 43 pediatric cases consisting of 64 high-grade astrocytomas and 71 non-astrocytomas) for the P53 Arg72Pro polymorphisms.
  • (ii) that there was a significant increase in the Arg/Pro heterozygous genotype among high-grade astrocytomas compared with non-astrocytomas (P = 0.002); and (iii) that there was a significant increase in the Arg/Pro heterozygous genotype among high-grade astrocytomas containing transdominant as well as recessive p53 mutations compared with controls (P = 0.002).
  • Our results suggest a possible association between P53 Arg72Pro polymorphisms and susceptibility to brain tumors, particularly high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Codon / genetics. Genetic Predisposition to Disease / genetics. Polymorphism, Genetic / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Amino Acid Substitution / genetics. Child. Child, Preschool. DNA Mutational Analysis. Female. Gene Frequency / genetics. Genetic Testing. Genotype. Heterozygote. Humans. Infant. Infant, Newborn. Male. Middle Aged. Mutation / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15950766.001).
  • [ISSN] 0169-328X
  • [Journal-full-title] Brain research. Molecular brain research
  • [ISO-abbreviation] Brain Res. Mol. Brain Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U10 CA13539-29; United States / NCI NIH HHS / CA / CA90290
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Codon; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


22. Miyajima Y, Sato Y, Oka H, Utsuki S, Kondo K, Tanizaki Y, Nagashio R, Tsuchiya B, Okayasu I, Fujii K: Prognostic significance of nuclear DJ-1 expression in astrocytoma. Anticancer Res; 2010 Jan;30(1):265-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of nuclear DJ-1 expression in astrocytoma.
  • The present study was conducted to determine whether any correlation exists between the expression of DJ-1 and WHO grading of the tumor or patient prognosis, and to analyze the function of this oncogene in astrocytomas.
  • Twenty-nine formalin-fixed and paraffin-embedded glioblastomas (grade IV), 21 anaplastic astorocytomas (grade III), and 14 diffuse astrocytomas (grade II) were immunohistochemically studied to identify the expression of DJ-1 protein.
  • The expression of DJ-1 was detected both in the nucleus and cytoplasm of tumor cells; however, such expression varied from case to case.
  • The present study demonstrated that the survival of patients with astrocytomas was correlated with the nuclear DJ-1 status of the tumor.
  • We herein demonstrated for the first time that the DJ-1 molecule might therefore play an important role as a tumor suppressor in astrocytomas.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Oncogene Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / metabolism. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Predictive Value of Tests. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150646.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Oncogene Proteins; 0 / PARK7 protein, human
  •  go-up   go-down


23. Gathinji M, McGirt MJ, Attenello FJ, Chaichana KL, Than K, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A: Association of preoperative depression and survival after resection of malignant brain astrocytoma. Surg Neurol; 2009 Mar;71(3):299-303, discussion 303
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of preoperative depression and survival after resection of malignant brain astrocytoma.
  • It remains unclear if clinical depression affects survival after surgical management of malignant brain astrocytoma.
  • METHODS: One thousand fifty-two patients undergoing surgical management for malignant brain astrocytoma (WHO grade 3 or 4) performed at a single institution from 1995 to 2006 were retrospectively reviewed.
  • Pathology was WHO grade IV in 829 (79%) and grade III in 223 (21%).
  • Adjusting for all variables associated with survival in this model, age (P < .001), KPS (P < .001), WHO grade III vs IV (P < .001), primary versus secondary resection (P < .001), gross-total resection (P < .001), Gliadel wafer implantation (P = .048), postoperative temozolomide therapy (P < .001), and subsequent resection at time of recurrence (P < .001); preoperative depression was independently associated with decreased survival (relative risk [95% CI]: 1.41 [1.1-1.96], P < .05).
  • CONCLUSION: In our experience, patients who are actively depressed at the time of surgery were associated with decreased survival after surgical management of malignant astrocytoma, independent of degree of disability, tumor grade, or subsequent treatment modalities.
  • [MeSH-major] Astrocytoma / mortality. Brain Neoplasms / mortality. Depression / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Morbidity. Preoperative Care. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18786716.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Combs SE, Nagy M, Edler L, Rausch R, Bischof M, Welzel T, Debus J, Schulz-Ertner D: Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors. Radiother Oncol; 2008 Aug;88(2):177-82
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative evaluation of radiochemotherapy with temozolomide versus standard-of-care postoperative radiation alone in patients with WHO grade III astrocytic tumors.
  • Outcome after radiochemotherapy (RCHT) with temozolomide (TMZ) versus radiotherapy (RT) for WHO grade III astrocytic tumors was evaluated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Dacarbazine / analogs & derivatives
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Disease Progression. Female. Humans. Male. Middle Aged. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18395280.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


25. Hlobilkova A, Ehrmann J, Knizetova P, Krejci V, Kalita O, Kolar Z: Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression. Neoplasma; 2009;56(4):284-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astrocytoma pathogenesis and progression.
  • Astrocytomas, particularly high grade astrocytoma, are brain tumors with potent angiogenic activity.
  • Our immnunohistochemical study assessed vascular endothelial growth factor (VEGF), VEGF receptors (Flk-1, and Flt-1), the intermediate filamental protein nestin which plays a role in central nervous system development, and MMP-9, which belongs the family of matrix metalloproteinases implicated in tumor invasion and angiogenesis regulation.
  • We investigated the expression of VEGF, its receptors, nestin and MMP-9 in astrocytomas and their correlation with tumor grade.
  • We used paraffin-embedded samples from 66 patients, 29 with low grade (WHO-grade II) and 37 with high grade (WHO-grade III and IV) astrocytomas.
  • Expression of Flt-1 and Flk-1 showed no significant differences between low and high grade tumor groups.
  • Expression of VEGF and MMP-9 was increased in the high grade group (p equal to or less than 0.026 and 0.024).
  • Nestin expression in tumor astrocytes and endothelial cells increased in high grade group (p same 0.007 and 0.003).
  • Higher expression of VEGF in high grade astrocytomas may subsequently lead to activation of survival, angiogenesis and migration.
  • Expression of nestin and MMP-9 also suggest their likely role in astrocytoma vascular development and proliferation.
  • [MeSH-major] Astrocytoma / etiology. Brain Neoplasms / etiology. Intermediate Filament Proteins / metabolism. Matrix Metalloproteinase 9 / metabolism. Nerve Tissue Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism. Vascular Endothelial Growth Factor Receptor-1 / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Disease Progression. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Nestin. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473053.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / FLT1 protein, human; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


26. Jager B, Schuhmann MU, Schober R, Kortmann RD, Meixensberger J: Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood. Pediatr Neurosurg; 2008;44(2):153-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of gliosarcoma and atypical meningioma 13 years after radiotherapy of residual pilocytic astrocytoma in childhood.
  • METHODS AND RESULTS: We report a patient who underwent subtotal resection of a right temporal and insular pilocytic astrocytoma at age 8 in 1988 followed by high-dose radiation therapy.
  • A local recurrence, grade WHO III, with signs of focal sarcomatous transformation, was subtotally resected 13 years later in 2001.
  • A new and fast growing right frontal meningioma, grade WHO II, was removed in 2003.
  • Another tumor mass reduction in 2005 was followed by stereotactic radiotherapy.
  • Irradiation-induced meningiomas in children are known to occur, however not following radiotherapy of low-grade hemispheric gliomas.
  • The presented case illustrates why adjuvant radiotherapy of residual pilocytic astrocytoma in children is not recommended anymore.
  • [MeSH-major] Astrocytoma / radiotherapy. Gliosarcoma / etiology. Meningeal Neoplasms / etiology. Meningioma / etiology. Neoplasms, Radiation-Induced / etiology
  • [MeSH-minor] Adult. Humans. Male. Radiotherapy / adverse effects


27. Desjardins A, Quinn JA, Vredenburgh JJ, Sathornsumetee S, Friedman AH, Herndon JE, McLendon RE, Provenzale JM, Rich JN, Sampson JH, Gururangan S, Dowell JM, Salvado A, Friedman HS, Reardon DA: Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. J Neurooncol; 2007 May;83(1):53-60
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.
  • We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG).
  • PATIENTS AND METHOD: Patients with grade III MG at any recurrence, received imatinib mesylate plus hydroxyurea (500 mg twice a day) orally on a continuous, daily schedule.
  • The most common grade 3 or greater toxicities were hematologic and complicated less than 4% of administered courses.
  • CONCLUSION: Imatinib mesylate plus hydroxyurea, is well tolerated and associated with anti-tumor activity in some patients with recurrent grade 3 MG.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Central Nervous System Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Benzamides. Female. Follow-Up Studies. Humans. Hydroxyurea / administration & dosage. Imatinib Mesylate. Male. Middle Aged. Neoplasm Recurrence, Local. Piperazines / administration & dosage. Prognosis. Pyrimidines / administration & dosage. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):57-63 [9422558.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):420-33 [11466698.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Lancet. 2003 Jan 25;361(9354):323-31 [12559880.001]
  • [Cites] Nat Med. 2006 Aug;12(8):908-16 [16862153.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Clin Oncol. 1999 Sep;17 (9):2762-71 [10561351.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):618-34 [15497115.001]
  • [Cites] Cancer Treat Rev. 2005 Apr;31(2):79-89 [15847978.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2572-8 [10561324.001]
  • [Cites] J Neurosurg. 1979 Oct;51(4):526-32 [225456.001]
  • [Cites] Semin Oncol. 1992 Jun;19(3 Suppl 9):34-9 [1641655.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • (PMID = 17245623.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA11898; United States / NCRR NIH HHS / RR / M01 RR30; United States / NINDS NIH HHS / NS / NS20023; United States / NCI NIH HHS / CA / P50-CA108786-01
  • [Publication-type] Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


28. Chen J, Huang SL, Li T, Chen XL: In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry. Neuroradiology; 2006 May;48(5):312-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry.
  • INTRODUCTION: Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading.
  • Proton magnetic resonance spectroscopy ((1)H-MRS) gives completely different information, relating to cell membrane proliferation, neuronal damage, energy metabolism and necrotic transformation of brain or tumor tissues.
  • The aim of this study was to investigate the relationship between (1)H-MRS and tumor proliferative potential in astrocytomas.
  • The tumor in 26 of these patients was classified as grade I/II (low grade), and the tumor in the remaining patients as grade III/IV (high grade) according to the World Health Organization classification criteria of nervous system tumors (2000).
  • The tumor in 21 patients was homogeneous astrocytoma, and of these 17 were classified as low grade and 4 as high grade.
  • RESULTS: The ratios of choline (Cho) to N-acetylaspartate (NAA) and Cho to creatine (Cr) in those with high-grade astrocytomas (n=4) were significantly higher than in those with low-grade astrocytomas (n=17) (t=2.899, P=0.009; t=3.96, P=0.001, respectively), and were found to be significantly correlated with the expression of PCNA in 21 patients with homogeneous astrocytomas (r=0.455, P=0.038; r=0.633, P=0.002, respectively).
  • CONCLUSIONS: We conclude that (1)H-MRS may be a valuable method for predicting preoperatively the degree of malignancy of homogeneous astrocytomas by enabling the calculation of the Cho/NAA and Cho/Cr ratios in vivo, and indirect evaluation of the tumor proliferative potential and prognosis, which are not available using conventional magnetic resonance imaging (MRI).
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aspartic Acid / analogs & derivatives. Aspartic Acid / metabolism. Child. Choline / metabolism. Creatine / metabolism. Female. Humans. Immunoenzyme Techniques. Magnetic Resonance Imaging. Male. Middle Aged. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2004 Apr;36(2):139-44 [15203749.001]
  • [Cites] Radiology. 1993 Mar;186(3):745-52 [8430183.001]
  • [Cites] Am J Clin Pathol. 1998 Jan;109(1):69-74 [9426520.001]
  • [Cites] J Comput Assist Tomogr. 1993 Mar-Apr;17(2):206-10 [8454746.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):377-80 [12532471.001]
  • [Cites] Neuroradiology. 2002 Aug;44(8):656-66 [12185543.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Dec;22(6):429-37 [11147296.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):172-82 [15484695.001]
  • [Cites] Radiology. 1990 Sep;176(3):791-9 [2389038.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):217-36 [12187957.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):39-46 [15696968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):9023-7 [12853570.001]
  • [Cites] Stereotact Funct Neurosurg. 2004;82(2-3):90-7 [15305081.001]
  • [Cites] Neuroradiology. 2002 May;44(5):371-81 [12012120.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] Histopathology. 1994 Oct;25(4):349-55 [7835840.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Apr;21(4):659-65 [10782774.001]
  • [Cites] J Neurosurg. 1997 Oct;87(4):516-24 [9322842.001]
  • [Cites] Acad Radiol. 2005 Jan;12(1):51-7 [15691725.001]
  • (PMID = 16552583.001).
  • [ISSN] 0028-3940
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


29. Hara A, Saegusa M, Ichinoe M, Okayasu I: Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours. J Clin Pathol; 2008 Mar;61(3):287-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
  • AIM: Definitive distinction between low-grade astrocytoma and astrogliosis is a long-standing difficulty due to their similar histopathological characteristics.
  • To clarify differences in biological significance, this study focused on various components of the cell cycle machinery and proliferation as key parameters, comparing expression in astrogliosis, as well as low- and high-grade astrocytomas.
  • METHODS: The expression of p16, p21 and p27, and cyclin A, cyclin D1, cyclin E, Rb and Ki-67 was immunohistochemically examined in 40 cases of astrogliosis and 48 cases of low-grade astrocytomas (grade II), as well as 50 high-grade tumours (grades III and IV).
  • RESULTS: Cell proliferation determined by Ki-67 immunoreactivity did not differ between astrogliosis and low-grade tumours.
  • Average labelling indices (LIs) for p16, p21, Rb, cyclin A and cyclin E showed a stepwise increase from astrogliosis, through low- to high-grade astrocytomas, indicating the possibility that over 9%, 6% and 4% of LIs for p16, p21 and cyclin A, respectively, may be useful predictors in the case of the latter, in contrast to significant decrease in p27 LIs.
  • Significantly higher mean LI values for cyclin D1 were also evident in astrogliosis (12.42) as compared with astrocytomas (low grade, 2.26; high grade, 4.60).
  • Positive correlations between LIs for Rb and Ki-67 were observed with astrogliosis and low- but not high-grade tumours.
  • In addition, high cyclin A LI values were independently associated with poor outcome in low-grade tumours.
  • CONCLUSION: These findings provide evidence that expression of cell-cycle-related molecules may be a reliable parameter for differential diagnosis of low-grade astrocytomas and astrogliosis.
  • Moreover, detection of cyclin A appears to be useful for predicting behaviour of low-grade astrocytomas.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor. Cyclin A / genetics. Gene Expression Regulation, Neoplastic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Cell Proliferation. Cyclin D1 / analysis. Cyclin D1 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / analysis. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Ki-67 Antigen / genetics. Male. Middle Aged. Precancerous Conditions / genetics. Precancerous Conditions / mortality. Precancerous Conditions / pathology. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retinoblastoma Protein / genetics. Statistics, Nonparametric. Survival Rate

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156430.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Ki-67 Antigen; 0 / Retinoblastoma Protein; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


30. Matar E, Cook RJ, Fowler AR, Biggs MT, Little NS, Wheeler HR, Robinson BG, McDonald KL: Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma. J Clin Neurosci; 2010 Aug;17(8):993-6
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-contrast enhancement as a clinical indicator of prognosis in patients with anaplastic astrocytoma.
  • Diagnosis of an anaplastic astrocytoma (World Health Organization grade III) is associated with a highly variable prognosis.
  • In this study, we analysed 48 patients with a histological diagnosis of anaplastic astrocytoma and found peritumoral post-gadolinium contrast enhancement to be a clear prognostic marker of poor prognosis.
  • The survival differences observed in the enhancing and non-enhancing lesions in patients diagnosed with anaplastic astrocytoma supports the existence of a broad anaplastic spectrum of disease, with enhancement being a clinical marker of tumour progression along this spectrum.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Gadolinium. Image Enhancement
  • [MeSH-minor] Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605464.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


31. Tehrani M, Friedman TM, Olson JJ, Brat DJ: Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol; 2008 Apr;18(2):164-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma.
  • Intravascular thrombosis is a frequent finding in glioblastoma [GBM; World Health Organization (WHO) grade IV] specimens and could potentially be involved in astrocytoma progression to GBM or represent a surrogate marker of GBM histology.
  • We investigated whether intravascular thrombosis was more frequent or prominent in GBM than other central nervous system (CNS) malignancies and considered its prognostic significance in anaplastic astrocytoma (AA; WHO grade III), which lacks necrosis.
  • Histologic sections were examined for thrombosis, necrosis and microvascular hyperplasia from each of 297 CNS tumors, including 103 GBMs, 46 AAs, 20 diffuse astrocytoma (DAs; WHO grade II), eight anaplastic oligodendrogliomas (AOs; WHO grade III), 20 oligodendrogliomas (ODs; WHO grade II), 49 metastatic carcinomas (METs), 31 primary central nervous system lymphomas (PCNSLs) and 20 medulloblastomas (MBs).

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] Cancer Res. 2006 Mar 1;66(5):2584-91 [16510576.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39 [16783163.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10643-6 [17108099.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 May;62(2):126-36 [17293122.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Proc Staff Meet Mayo Clin. 1949 Feb 2;24(3):71-5 [18111063.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Thromb Res. 2001 Jun 15;102(6):V215-24 [11516455.001]
  • [Cites] Curr Opin Pulm Med. 2001 Sep;7(5):326-31 [11584184.001]
  • [Cites] J Neurosurg. 1991 Mar;74(3):480-6 [1899696.001]
  • [Cites] Nature. 1992 Oct 29;359(6398):845-8 [1279432.001]
  • [Cites] Neurosurgery. 1995 Feb;36(2):375-80; discussion 380-1 [7731519.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):115-8 [8958516.001]
  • [Cites] J Pathol Bacteriol. 1954 Jul;68(1):231-3 [13212575.001]
  • [Cites] Acta Pathol Microbiol Scand. 1950;27(1):51-64 [15406242.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1406-13 [15735028.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):321-5 [12135696.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 [12182418.001]
  • [Cites] Ann Intern Med. 2003 Apr 15;138(8):659-68 [12693889.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):920-7 [14871821.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1147-52 [15001257.001]
  • [Cites] Lab Invest. 2004 Apr;84(4):397-405 [14990981.001]
  • [Cites] Cancer. 1983 Aug 1;52(3):550-4 [6305479.001]
  • [Cites] Cancer. 1987 May 1;59(9):1617-25 [3030531.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • (PMID = 18093251.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS053727-01; United States / NINDS NIH HHS / NS / R01 NS053727; United States / NINDS NIH HHS / NS / NS053727; United States / NINDS NIH HHS / NS / R01 NS053727-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS82090; NLM/ PMC2610479
  •  go-up   go-down


32. Sharma S, Sharma MC, Gupta DK, Sarkar C: Angiogenic patterns and their quantitation in high grade astrocytic tumors. J Neurooncol; 2006 Aug;79(1):19-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic patterns and their quantitation in high grade astrocytic tumors.
  • BACKGROUND: The objectives of this study on high grade astrocytic tumors were (i) to establish differences, if any, between grades III & IV tumors among angiogenic parameters, both qualitative and quantitative, and (ii) to correlate angiogenic parameters with proliferation indices, namely T2a and MIB1 labeling indices.
  • DESIGN: Twenty nine consecutive cases of WHO grades III (11) and IV (18) astrocytic tumors diagnosed in the year-2004 were studied, using H&E and CD34, MIB1 and T2a immunostaining by streptavidin biotin technique.
  • Statistically significant differences (P<0.05) were seen between grades III and IV in iMVD, aspect, MD and FD, but not in angiogenic patterns or MVA (P = 0.27).
  • Intratumoral endothelial MIB1 LI was significantly higher in grade IV as compared to grade III, but did not correlate with angiogenic parameters.
  • Limited follow up data showed all recurrent grade IV tumors to be of glomeruloid type.
  • CONCLUSION: Increased angiogenesis in grade IV, as compared to grade III, astrocytic tumors is characterized by an increased number/density of vessels: an increase in vessels characterized by disproportionate lengthening and likely associated with the infiltrative properties of the tumors; and an increase in pliable, irregularly shaped or structured vessels.
  • The lack of correlation of these angiogenesis parameters with the MIB1 and T2a proliferation indices reflects the complexity of angiogenesis parameters in high grade gliomas.
  • Further studies are needed to determine the usefulness of the angiogenic parameters in the improved diagnosis (grading) and prognosis of astrocytic tumors.
  • [MeSH-major] Astrocytoma / blood supply. Astrocytoma / pathology. Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Neovascularization, Pathologic
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Female. Humans. Image Processing, Computer-Assisted. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1998 Apr;29(4):352-8 [9563784.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1216-21 [15026804.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Clin Neurosurg. 1976;23:440-53 [975695.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):401-9 [7688183.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Acta Neuropathol. 1989;77(4):369-78 [2469286.001]
  • [Cites] Histopathology. 2001 Oct;39(4):402-8 [11683942.001]
  • [Cites] Brain Pathol. 1994 Jul;4(3):207-18 [7524960.001]
  • [Cites] Ai Zheng. 2005 Jan;24(1):19-22 [15642194.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):289-96 [12609567.001]
  • [Cites] Anal Cell Pathol. 1992 Nov;4(6):409-19 [1457384.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):75-85 [8699229.001]
  • [Cites] Am J Clin Pathol. 2004 Nov;122(5):675-7 [15491962.001]
  • [Cites] J Pathol. 1992 Nov;168(3):257-62 [1281874.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):477-82 [10470824.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):513-20 [9488306.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):487-93 [2552044.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):134-41 [10393366.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] Tumori. 2001 Jan-Feb;87(1):47-53 [11669558.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):46-52 [15850004.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):165-72 [11245275.001]
  • [Cites] J Clin Pathol. 2002 Jul;55(7):530-4 [12101201.001]
  • [Cites] Leukemia. 2003 Jan;17(1):89-97 [12529665.001]
  • [Cites] Endocr Pathol. 2003 Fall;14(3):239-47 [14586069.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66 [11849564.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):516-26 [14595708.001]
  • [Cites] Biochem J. 1994 Nov 1;303 ( Pt 3):681-95 [7980433.001]
  • [Cites] Histopathology. 2003 Apr;42(4):395-402 [12653952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):193-207 [8380567.001]
  • [Cites] J Neurooncol. 1997 May;32(3):253-65 [9049887.001]
  • [Cites] Clin Exp Dermatol. 2003 May;28(3):310-4 [12780721.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):426-9 [15043465.001]
  • [Cites] Am J Pathol. 1988 Nov;133(2):419-23 [3189515.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):902-9 [7525899.001]
  • [Cites] Adv Pharmacol. 1990;21:149-83 [2176094.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1369-76 [11516097.001]
  • [Cites] Lancet. 1992 Jul 18;340(8812):145-6 [1378165.001]
  • [Cites] Histopathology. 2005 May;46(5):481-9 [15842629.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):101-5 [10912927.001]
  • [Cites] N Engl J Med. 1991 Jan 3;324(1):1-8 [1701519.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):133-43 [12744467.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):2941-55 [15126324.001]
  • [Cites] Acta Neuropathol. 1993;85(5):508-14 [7684179.001]
  • (PMID = 16807783.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Pipas JM, Meyer LP, Rhodes CH, Cromwell LD, McDonnell CE, Kingman LS, Rigas JR, Fadul CE: A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. J Neurooncol; 2005 Feb;71(3):301-5
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • PURPOSE: Therapy for high-grade gliomas remains unsatisfactory.
  • We conducted a Phase II trial of these agents in combination with filgrastim (G-CSF) in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma.
  • PATIENTS AND METHODS: Adult patients with radiographic evidence of recurrent or progressive tumor following primary therapy were eligible for study.
  • Hematologic toxicity was common with 25 /% of patients experiencing grade III or IV leukopenia despite G-CSF support.
  • CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma.
  • The significant hematotoxicity encountered, however, cannot justify further investigation of this combination in patients with high grade brain tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Disease-Free Survival. Drug Resistance, Neoplasm / drug effects. Female. Filgrastim. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Leukopenia / chemically induced. Male. Middle Aged. Paclitaxel / administration & dosage. Recombinant Proteins. Thrombocytopenia / chemically induced. Topotecan / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Anaplastic Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):980-6 [12095566.001]
  • [Cites] J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24 [7932806.001]
  • [Cites] Cancer Chemother Pharmacol. 1994;34(2):171-4 [8194169.001]
  • [Cites] Oncologist. 2003;8(1):76-82 [12604734.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3121-8 [9294475.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1964-5 [8656268.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):923-7 [11521796.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1893-900 [11283120.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):725-7 [8428353.001]
  • [Cites] J Clin Oncol. 1995 Sep;13(9):2230-7 [7545219.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):188-96 [11592339.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20 [1331485.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2032-7 [9626200.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2066-71 [7636549.001]
  • [Cites] Biometrics. 1993 Sep;49(3):741-52 [8241370.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):539-43 [8120551.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):600-9 [8636777.001]
  • [Cites] Cancer Res. 1994 Oct 1;54(19):5118-22 [7923128.001]
  • [Cites] Drugs. 1995 Jan;49(1):11-9 [7705211.001]
  • [Cites] Cancer. 2001 Jan 15;91(2):417-22 [11180089.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2188-94 [9626220.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2585-97 [8453582.001]
  • [Cites] Expert Opin Pharmacother. 2001 Mar;2(3):491-505 [11336601.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):113-9 [11516860.001]
  • (PMID = 15735921.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


34. Tendulkar RD, Pai Panandiker AS, Wu S, Kun LE, Broniscer A, Sanford RA, Merchant TE: Irradiation of pediatric high-grade spinal cord tumors. Int J Radiat Oncol Biol Phys; 2010 Dec 01;78(5):1451-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irradiation of pediatric high-grade spinal cord tumors.
  • PURPOSE: To report the outcome using radiation therapy (RT) for pediatric patients with high-grade spinal cord tumors.
  • METHODS AND MATERIALS: A retrospective chart review was conducted that included 17 children with high-grade spinal cord tumors treated with RT at St. Jude Children's Research Hospital between 1981 and 2007.
  • The tumor diagnosis was glioblastoma multiforme (n = 7), anaplastic astrocytoma (n = 8), or anaplastic oligodendroglioma (n = 2).
  • Local tumor progression at 12 months (79% vs. 30%, p = 0.02) and median survival (13.1 vs. 27.2 months, p = 0.09) were worse for patients with glioblastoma multiforme compared with anaplastic astrocytoma or oligodendroglioma.
  • Three long-term survivors with World Health Organization Grade III tumors were alive with follow-up, ranging from 88-239 months.
  • CONCLUSIONS: High-grade spinal cord primary tumors in children have a poor prognosis.
  • [MeSH-major] Astrocytoma / radiotherapy. Oligodendroglioma / radiotherapy. Spinal Cord Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Glioblastoma / mortality. Glioblastoma / pathology. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Male. Prognosis. Radiotherapy Dosage. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • [Cites] J Neurosurg. 1987 Apr;66(4):621-5 [3031241.001]
  • [Cites] Pediatr Neurosurg. 1999 Jan;30(1):1-5 [10202299.001]
  • [Cites] Neurol Med Chir (Tokyo). 1990 Jul;30(7):489-94 [1701860.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):590-5 [7674006.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 May;27(5):254-8 [15891559.001]
  • [Cites] Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7 [12182772.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jul 15;41(5):1005-11 [9719109.001]
  • [Cites] Arch Neurol. 1978 Apr;35(4):244-5 [205201.001]
  • [Cites] J Neurooncol. 1997 Jul;33(3):205-11 [9195492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):845-50 [9531369.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):997-1007 [6349785.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jun;16(6):1397-403 [2542194.001]
  • [Cites] J Neurosurg. 1979 Oct;51(4):437-45 [479930.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1535-43 [8608540.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] Spinal Cord. 2005 Sep;43(9):565-7 [15838531.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):732-5 [7093908.001]
  • [Cites] Neurosurgery. 1991 Feb;28(2):302-6 [1847741.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1060-71 [16373081.001]
  • [Cites] J Neurosurg. 1996 Dec;85(6):1036-43 [8929492.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 1;73(3):727-33 [18687533.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):179-83 [15925999.001]
  • [Cites] Childs Nerv Syst. 2006 Jul;22(7):652-61 [16565851.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):323-8 [7673019.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):313-9 [16200343.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):403-7 [16609952.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2391-9 [9840540.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Nov 1;60(3):853-60 [15465203.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] J Neurosurg. 1998 Feb;88(2):215-20 [9452226.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):50-4 [2909688.001]
  • (PMID = 20346593.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Cho KH, Kim JY, Lee SH, Yoo H, Shin SH, Moon SH, Kim TH, Shin KH, Yoon M, Lee DH, Pyo HR: Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys; 2010 Oct 1;78(2):390-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas.
  • PURPOSE: We analyzed outcomes of simultaneous integrated boost (SIB) intensity-modulated radiotherapy (IMRT) in patients with high-grade gliomas, compared with a literature review.
  • METHODS AND MATERIALS: Forty consecutive patients (WHO grade III, 14 patients; grade IV, 26 patients) treated with SIB-IMRT were analyzed.
  • A dose of 2.0 Gy was delivered to the planning target volume with a SIB of 0.4 Gy to the gross tumor volume with a total dose of 60 Gy to the gross tumor volume and 50 Gy to the planning target volume in 25 fractions during 5 weeks.
  • One- and 2-year survival rates were 78% and 65%, respectively, for patients with grade III tumors and 56% and 31%, respectively, for patients with grade IV tumors.
  • Age (≤50 vs. >50), grade (III vs. IV), subtype (astrocytoma vs. oligodendroglioma or mixed), and a Zubrod performance score (0-1 vs. >2) were predictive of survival.
  • [MeSH-major] Astrocytoma / radiotherapy. Brain Neoplasms / radiotherapy. Oligodendroglioma / radiotherapy. Radiotherapy, Intensity-Modulated / methods
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20097489.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Number-of-references] 20
  •  go-up   go-down


36. Raco A, Piccirilli M, Landi A, Lenzi J, Delfini R, Cantore G: High-grade intramedullary astrocytomas: 30 years' experience at the Neurosurgery Department of the University of Rome "Sapienza". J Neurosurg Spine; 2010 Feb;12(2):144-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade intramedullary astrocytomas: 30 years' experience at the Neurosurgery Department of the University of Rome "Sapienza".
  • OBJECT: The goal in this study was to review a series of patients who underwent surgical removal of intramedullary high-grade gliomas, focusing on the functional outcome, recurrence rates, and technical problems continually debated in neurosurgical practice.
  • METHODS: Between December 1976 and December 2006, 22 patients underwent removal of intramedullary high-grade gliomas.
  • RESULTS: Histological examinations showed 10 Grade III astrocytomas and 12 glioblastomas.
  • Only 2 of the 22 high-grade astrocytomas could be completely removed.
  • In this series, multimodality treatment of intramedullary high-grade astrocytomas has been shown to increase length of survival without improving the neurological status.
  • [MeSH-major] Astrocytoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cervical Vertebrae. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Neurosurgical Procedures / mortality. Rome. Spinal Cord / pathology. Spinal Cord / surgery. Thoracic Vertebrae. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg Spine. 2010 Feb;12(2):141-2; discussion 142-3 [20121347.001]
  • (PMID = 20121348.001).
  • [ISSN] 1547-5646
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Watanabe Y, Yamasaki F, Kajiwara Y, Saito T, Nishimoto T, Bartholomeusz C, Ueno NT, Sugiyama K, Kurisu K: Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol; 2010 Dec;100(3):449-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis.
  • Despite its many important roles, the clinical significance of PEA-15 expression levels in astrocytic tumors has yet to be properly defined.
  • We studied the PEA-15 expression pattern of 65 patients [diagnosed according to World Health Organization (WHO) criteria] with diffuse astrocytoma (WHO grade II), anaplastic astrocytoma (grade III), and glioblastoma (grade IV).
  • In grade II astrocytoma (diffuse astrocytoma) and grade III astrocytoma (anaplastic astrocytoma), 100% and 88.9% of patients expressed high PEA-15 levels, respectively, while a smaller number (50%) of patients with grade IV astrocytoma (glioblastoma) expressed high PEA-15 levels.
  • PEA-15 expression level was inversely associated with WHO grade (P = 0.0006).
  • Next, we evaluated prognosis and PEA-15 expression levels in 43 patients with high-grade astrocytomas based on the following parameters: age, gender, WHO grade, surgical resection extent, MIB-1 labeling index (LI), and PEA-15 expression level.
  • Multivariable analyses revealed that high PEA-15 expression level displayed a significant correlation with longer overall survival (OS) in high-grade astrocytomas (P = 0.0024).
  • In conclusion, PEA-15 expression level was inversely associated with WHO grade and may serve as an important prognostic factor for high-grade astrocytomas.
  • [MeSH-major] Astrocytoma / diagnosis. Astrocytoma / metabolism. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Phosphoproteins / metabolism. Statistics as Topic
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Ki-67 Antigen / metabolism. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Severity of Illness Index. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Health Statistics.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] J Neurosci. 1999 Oct 1;19(19):8244-51 [10493725.001]
  • [Cites] J Biol Chem. 2002 Jul 12;277(28):25020-5 [11976344.001]
  • [Cites] Radiother Oncol. 2007 Dec;85(3):371-8 [18035440.001]
  • [Cites] Mol Cancer Ther. 2008 May;7(5):1013-24 [18445660.001]
  • [Cites] Oncogene. 2005 Oct 27;24(47):7012-21 [16044159.001]
  • [Cites] Oncogene. 2008 Feb 14;27(8):1155-66 [17700518.001]
  • [Cites] Mol Biol Cell. 2006 Dec;17(12):5141-52 [16987961.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(11):5005-15 [15143191.001]
  • [Cites] J Neurochem. 1998 Sep;71(3):1307-14 [9721757.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):322-7 [15863380.001]
  • [Cites] Mol Cell Biol. 2003 Jul;23(13):4511-21 [12808093.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1162-70 [11221847.001]
  • [Cites] Biochem J. 2005 Sep 15;390(Pt 3):729-35 [15916534.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1536-44 [17308092.001]
  • [Cites] Oncogene. 1999 Aug 5;18(31):4409-15 [10442631.001]
  • [Cites] J Cell Mol Med. 2008 Dec;12(6A):2416-26 [18284607.001]
  • [Cites] Dev Cell. 2001 Aug;1(2):239-50 [11702783.001]
  • [Cites] Mol Biol Cell. 2005 Aug;16(8):3552-61 [15917297.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9302-10 [19010903.001]
  • [Cites] Neuropathology. 2008 Oct;28(5):507-15 [18410277.001]
  • [Cites] J Biol Chem. 1993 Mar 15;268(8):5911-20 [8449955.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12840-7 [14707138.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1491-9 [16452205.001]
  • [Cites] Int J Cancer. 2007 Mar 15;120(6):1215-22 [17192900.001]
  • (PMID = 20455002.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / PEA15 protein, human; 0 / Phosphoproteins
  •  go-up   go-down


38. Martínez C, Molina JA, Alonso-Navarro H, Jiménez-Jiménez FJ, Agúndez JA, García-Martín E: Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma. BMC Neurol; 2010;10:71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two common nonsynonymous paraoxonase 1 (PON1) gene polymorphisms and brain astrocytoma and meningioma.
  • Aiming to identify genetic variations related to the risk of developing brain tumors, we investigated the putative association between common nonsynonymous PON1 polymorphisms and the risk of developing astrocytoma and meningioma.
  • METHODS: Seventy one consecutive patients with brain tumors (43 with astrocytoma grade II/III and 28 with meningioma) with ages ranging 21 to 76 years, and 220 healthy controls subjects were analyzed for the frequency of the nonsynonymous PON1 genotypes L55M rs854560 and Q192R rs662.
  • All participants were adult Caucasian individuals recruited in the central area of Spain.
  • RESULTS: The frequencies of the PON1 genotypes and allelic variants of the polymorphisms PON1 L55M and PON1 Q192R did not differ significantly between patients with astrocytoma and meningioma and controls.
  • The minor allele frequencies were as follows: PON1 55L, 0.398, 0.328 and 0.286 for patients with astrocytoma, meningioma and control individuals, respectively; PON1 192R, 0.341, 0.362 and 0.302 for patients with astrocytoma, meningioma and control individuals, respectively.
  • Haplotype association analyses did not identify any significant association with the risk of developing astrocytoma or meningioma.
  • CONCLUSIONS: Common nonsynonymous PON1 polymorphisms are not related with the risk of developing astrocytoma and meningioma.
  • [MeSH-major] Aryldialkylphosphatase / genetics. Astrocytoma / genetics. Brain Neoplasms / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Polymerase Chain Reaction. Polymorphism, Single Nucleotide. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 1998 Sep;34(3):252-60 [9698994.001]
  • [Cites] Atherosclerosis. 1998 Aug;139(2):341-9 [9712341.001]
  • [Cites] Biochem Pharmacol. 1998 Sep 1;56(5):547-51 [9783722.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):116-25 [15386358.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Environ Health Perspect. 2005 May;113(5):546-51 [15866761.001]
  • [Cites] Environ Health Perspect. 2005 Jul;113(7):909-13 [16002382.001]
  • [Cites] Liver Int. 2005 Oct;25(5):935-9 [16162149.001]
  • [Cites] Toxicology. 2005 Nov 15;215(3):182-90 [16102884.001]
  • [Cites] Occup Environ Med. 2005 Nov;62(11):786-92 [16234405.001]
  • [Cites] World J Gastroenterol. 2006 Jan 28;12(4):615-20 [16489678.001]
  • [Cites] Acta Neurol Scand. 2006 May;113(5):322-6 [16629768.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1513-6 [16685388.001]
  • [Cites] Pharmacogenomics. 2006 Jul;7(5):711-8 [16886896.001]
  • [Cites] Cell Biochem Funct. 2006 Sep-Oct;24(5):455-60 [16142697.001]
  • [Cites] J Agric Saf Health. 2006 Nov;12(4):255-74 [17131948.001]
  • [Cites] Drug Metab Dispos. 2007 Feb;35(2):315-20 [17132760.001]
  • [Cites] Occup Environ Med. 2007 Aug;64(8):509-14 [17537748.001]
  • [Cites] Am J Hum Genet. 2007 Sep;81(3):559-75 [17701901.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 2007 Jan-Mar;10(1-2):81-99 [18074305.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jan;18(1):37-43 [18216720.001]
  • [Cites] Am J Epidemiol. 2008 Apr 15;167(8):976-85 [18299277.001]
  • [Cites] Clin Chem. 2008 Aug;54(8):1390-4 [18664443.001]
  • [Cites] Curr Drug Metab. 2008 Jul;9(6):520-31 [18680472.001]
  • [Cites] Neuro Oncol. 2008 Oct;10(5):709-15 [18682580.001]
  • [Cites] Psychiatr Genet. 2008 Dec;18(6):289-94 [19018234.001]
  • [Cites] Toxicol Appl Pharmacol. 2009 Apr 15;236(2):142-53 [19371602.001]
  • [Cites] Cell Biochem Funct. 2009 Dec;27(8):558-67 [19902425.001]
  • [Cites] Environ Health Perspect. 2010 Jan;118(1):144-9 [20056567.001]
  • [Cites] Adv Exp Med Biol. 2010;660:47-60 [20221870.001]
  • [Cites] Eur J Neurol. 2010 Jun 1;17(6):879-81 [20050883.001]
  • [Cites] Chem Biol Interact. 2010 Sep 6;187(1-3):355-61 [20338154.001]
  • [Cites] Neuromolecular Med. 2010 Sep;12(3):217-23 [19826962.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1999 Feb;45(1):15-23 [10099836.001]
  • [Cites] Pharmacogenetics. 2000 Dec;10(9):767-79 [11191881.001]
  • [Cites] J Lipid Res. 2001 Apr;42(4):528-35 [11290824.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 15;173(1):1-6 [11350209.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1323-6 [11470765.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):909-13 [11673119.001]
  • [Cites] Ann Diagn Pathol. 2002 Feb;6(1):44-8 [11842378.001]
  • [Cites] Curr Opin Lipidol. 2002 Aug;13(4):357-62 [12151850.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):214-27 [12210690.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):139-50 [12749719.001]
  • [Cites] Br J Neurosurg. 2003 Apr;17(2):182-4 [12820764.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1162-9 [14574645.001]
  • [Cites] J Mol Med (Berl). 2003 Dec;81(12):766-79 [14551701.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):434-42 [15026468.001]
  • [Cites] Am J Ind Med. 2004 May;45(5):395-407 [15095422.001]
  • [Cites] Curr Drug Metab. 2004 Jun;5(3):211-24 [15180491.001]
  • [Cites] Arch Pathol Lab Med. 1979 Dec;103(13):676-9 [583126.001]
  • [Cites] J Neurol. 1982;227(3):165-9 [6181224.001]
  • [Cites] Indian J Cancer. 1983 Mar;20(1A):86-8 [6873998.001]
  • [Cites] Am J Epidemiol. 1988 Oct;128(4):778-85 [3421243.001]
  • [Cites] Neurologia. 1988 Mar-Apr;3(2):68-70 [2856211.001]
  • [Cites] J Neurosci Nurs. 1992 Oct;24(5):260-4 [1328422.001]
  • [Cites] Am J Hum Genet. 1993 Mar;52(3):598-608 [7916578.001]
  • [Cites] Nat Genet. 1993 Jan;3(1):73-6 [8098250.001]
  • [Cites] Neurosurgery. 1995 Mar;36(3):599-604; discussion 604-5 [7753363.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4237-9 [7671227.001]
  • [Cites] J Neurosurg Sci. 1995 Mar;39(1):27-35 [8568553.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Curr Opin Lipidol. 1996 Apr;7(2):69-76 [8743898.001]
  • [Cites] Nat Genet. 1996 Nov;14(3):334-6 [8896566.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Nature. 1998 Jul 16;394(6690):284-7 [9685159.001]
  • (PMID = 20723250.001).
  • [ISSN] 1471-2377
  • [Journal-full-title] BMC neurology
  • [ISO-abbreviation] BMC Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.8.1 / Aryldialkylphosphatase; EC 3.1.8.1 / PON1 protein, human
  • [Other-IDs] NLM/ PMC2936881
  •  go-up   go-down


39. Rorive S, Maris C, Debeir O, Sandras F, Vidaud M, Bièche I, Salmon I, Decaestecker C: Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles. J Neuropathol Exp Neurol; 2006 Aug;65(8):794-807
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
  • Although World Health Organization (WHO) grade I pilocytic astrocytomas and grade II diffuse astrocytomas have been classified for decades as different clinicopathologic entities, few, if any, data are available on the biologic features explaining these differences.
  • Although more than 50 microarray-related studies have been carried out to characterize the molecular profiles of astrocytic tumors, we have identified only 11 that provide sound data on low-grade astrocytomas.
  • We have incorporated these data into a comparative analysis for the purpose of identifying the most relevant molecular markers characterizing grade I pilocytic and grade II diffuse astrocytomas.
  • Our analysis has identified various interesting genes that are differentially expressed in either grade I or grade II astrocytomas when compared with normal tissue and/or high-grade (WHO grade III and IV) astrocytomas.
  • Interestingly, a group of 6 genes (TIMP4, C1NH, CHAD, THBS4, IGFBP2, and TLE2) constitute an expression profile characteristic of grade I astrocytomas as compared with all other categories of tissue (normal brain, grade II, and high-grade astrocytomas).
  • The end products (proteins) of these genes act as antimigratory compounds, a fact that could explain why pilocytic astrocytomas behave as compact (well-circumscribed) tumors as opposed to all the other astrocytic tumor types that diffusely invade the brain parenchyma.
  • [MeSH-major] Astrocytoma / genetics. Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic / genetics. Genetic Predisposition to Disease / genetics
  • [MeSH-minor] Adult. Cell Adhesion / genetics. Cell Movement / genetics. Child. Extracellular Matrix Proteins / genetics. Extracellular Matrix Proteins / metabolism. Humans. Models, Neurological. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / physiopathology. Oligonucleotide Array Sequence Analysis / methods. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16896313.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins
  •  go-up   go-down


40. Christensen K, Schrøder HD, Kristensen BW: CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol; 2008 Nov;90(2):157-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD133 identifies perivascular niches in grade II-IV astrocytomas.
  • A retrospective analysis of 114 grade II, III and IV astrocytomas was undertaken.
  • There was no correlation between the mean volume fraction of CD133(+) niches and all CD133(+) tumour cells and tumour grade.
  • [MeSH-major] Antigens, CD / metabolism. Astrocytoma / pathology. Brain Neoplasms / pathology. Endothelium, Vascular / metabolism. Glycoproteins / metabolism. Peptides / metabolism
  • [MeSH-minor] AC133 Antigen. Adolescent. Adult. Aged. Analysis of Variance. Child. Child, Preschool. Female. Humans. Indoles. Intermediate Filament Proteins / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Nestin. Retrospective Studies. Survival Analysis. Ubiquitin-Protein Ligases / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2004 Jul;17(7):790-7 [15073602.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] J Comp Neurol. 2000 Oct 2;425(4):479-94 [10975875.001]
  • [Cites] Cell Tissue Res. 2005 Jan;319(1):15-26 [15558321.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Am J Clin Pathol. 2008 Mar;129(3):358-66 [18285257.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14 (1):123-9 [18172261.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Arch Pathol Lab Med. 2002 Jun;126(6):702-5 [12033959.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16466-71 [17056721.001]
  • [Cites] Science. 2004 May 28;304(5675):1338-40 [15060285.001]
  • [Cites] Cell. 2004 Mar 19;116(6):769-78 [15035980.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3560-4 [17440065.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):921-8 [15300804.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23 ):10946-51 [16322242.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10 ):733-6 [17882276.001]
  • [Cites] PLoS One. 2008 Apr 09;3(4):e1936 [18398462.001]
  • [Cites] Acta Cytol. 1989 Sep-Oct;33(5):576-82 [2476903.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Res. 2001 Dec 15;61(24):8664-7 [11751382.001]
  • [Cites] Br J Cancer. 1992 Aug;66(2):373-85 [1503912.001]
  • [Cites] APMIS. 1988 May;96(5):379-94 [3288247.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] J Histochem Cytochem. 2002 Feb;50(2):147-58 [11799134.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Acta Neurol Scand Suppl. 1992;137:8-13 [1357908.001]
  • [Cites] Neurosurgery. 2008 Feb;62(2):505-14; discussion 514-5 [18382330.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4553-7 [16651403.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 6;358(3):908-13 [17512905.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] J Histochem Cytochem. 1997 Nov;45(11):1455-9 [9358847.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):132-4 [3751697.001]
  • [Cites] Clin Neuropathol. 2004 Mar-Apr;23(2):47-52 [15074577.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4010-5 [17483311.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] J Clin Pathol. 2004 Sep;57(9):965-9 [15333659.001]
  • [Cites] Stem Cells. 2005 Jun-Jul;23 (6):791-804 [15917475.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Sep;65(9):846-54 [16957578.001]
  • [Cites] J Microsc. 1986 Jul;143(Pt 1):3-45 [3761363.001]
  • [Cites] Nature. 2004 Feb 19;427(6976):740-4 [14973487.001]
  • [Cites] J Microsc. 1987 Sep;147(Pt 3):229-63 [3430576.001]
  • [Cites] J Neurooncol. 2008 Jan;86(1):31-45 [17611714.001]
  • [Cites] Differentiation. 2001 Sep;68(2-3):141-52 [11686236.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12 ):5727-36 [17575139.001]
  • (PMID = 18612800.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 Antigen; 0 / Antigens, CD; 0 / Glycoproteins; 0 / Indoles; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / PROM1 protein, human; 0 / Peptides; 47165-04-8 / DAPI; EC 2.3.2.27 / MIB1 ligase, human; EC 2.3.2.27 / Ubiquitin-Protein Ligases
  •  go-up   go-down


41. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V, Oghaki H, Giangaspero F: Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol; 2010 Sep;99(2):209-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.
  • The objective of this study was to evaluate, in a series of 43 pediatric high-grade gliomas (21 anaplastic astrocytoma WHO grade III and 22 glioblastoma WHO grade IV), the prognostic value of histological grading and expression of p53 and YKL-40.
  • The prognostic stratification for histological grading showed no difference in overall (OS) and progression-free survival (PFS) between glioblastomas and anaplastic astrocytomas.
  • TP53 mutations were detected in five of 27 (18%) cases (four glioblastomas and one anaplastic astrocytoma).
  • Our results suggest that in pediatric high-grade gliomas: (i) histological grading does not have strong prognostic significance, (ii) YKL-40 overexpression is less frequent than adult high-grade gliomas and does not correlate with a more aggressive behavior, (iii) TP53 mutations but not p53 expression may correlate with a more aggressive behavior, and (iv) IDH1 mutations are absent.
  • These observations support the concept that, despite identical histological features, the biology of high-grade gliomas in children differs from that in adults, and therefore different prognostic factors are needed.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / metabolism. Glycoproteins / metabolism. Isocitrate Dehydrogenase / genetics. Lectins / metabolism. Mutation / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adipokines. Adolescent. Adult. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Child. Child, Preschool. Chitinase-3-Like Protein 1. DNA, Neoplasm / genetics. Female. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Male. Neoplasm Staging. Polymerase Chain Reaction. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Oncol Rep. 2009 Jan;11(1):68-72 [19080744.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):267-72 [16195804.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):888-93 [17554787.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Biochem J. 2002 Jul 1;365(Pt 1):119-26 [12071845.001]
  • [Cites] Hum Pathol. 1999 Nov;30(11):1284-90 [10571506.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6892-9 [15466178.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [Cites] Neuro Oncol. 2009 Jun;11(3):274-80 [18981259.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3326-34 [15867231.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] J Neurosurg. 1991 Jan;74(1):27-37 [1984503.001]
  • [Cites] Clin Cancer Res. 2006 Jul 1;12 (13):3935-41 [16818690.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6002-7 [19755387.001]
  • [Cites] Curr Probl Cancer. 2008 May-Jun;32(3):97-123 [18501774.001]
  • [Cites] Recent Results Cancer Res. 2009;171:67-81 [19322538.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1196-208 [17401009.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7404-7 [11606370.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):121-30 [8988090.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):264-71 [11815986.001]
  • [Cites] Neurosurgery. 1995 Aug;37(2):246-54 [7477776.001]
  • [Cites] Exp Cell Res. 1999 Jul 10;250(1):168-73 [10388530.001]
  • [Cites] N Engl J Med. 2002 Feb 7;346(6):420-7 [11832530.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6284-92 [17975139.001]
  • (PMID = 20174854.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adipokines; 0 / CHI3L1 protein, human; 0 / Chitinase-3-Like Protein 1; 0 / DNA, Neoplasm; 0 / Glycoproteins; 0 / Lectins; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


42. Shaffrey ME, Farace E, Schiff D, Larner JM, Mut M, Lopes MB: The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas. J Neurosurg; 2005 Jun;102(6):1033-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ki-67 labeling index as a prognostic factor in Grade II oligoastrocytomas.
  • OBJECT: This study was conducted to determine whether proliferative tumor activity, as assessed using the Ki-67 immunohistochemical labeling index (LI), has prognostic utility for patients with Grade II oligoastrocytomas.
  • In a retrospective analysis, the authors selected cases with biopsy-proven diagnoses of Grade II oligoastrocytomas on initial presentation.
  • Twenty-three adult patients were followed for at least 1 year (median 40.3 months).
  • Eleven patients with Grade II tumors and initial Ki-67 LIs less than 10% had a significantly longer median time to tumor progression (TTP, 51.8 months compared with 9.9 months) and a longer median survival (93.1 months compared with 16.1 months) than 12 patients with initial Ki-67 LIs of 10% or greater.
  • Twelve patients with Grade III oligoastrocytomas had a mean TTP that was similar to the TTP of patients with Grade II tumors and high Ki-67 LIs (mean 4 months compared with 9.9 months) and duration of survival (13.3 months compared with 16.1 months).
  • CONCLUSIONS: Patients with a Grade II oligoastrocytoma and a Ki-67 LI of 10% or greater have a much shorter TTP and potentially a poorer disease prognosis than expected--more similar to patients with a Grade III oligoastrocytoma.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Ki-67 Antigen / metabolism
  • [MeSH-minor] Adult. Age Distribution. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028762.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen
  •  go-up   go-down


43. Lee EJ, Lee SK, Agid R, Bae JM, Keller A, Terbrugge K: Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol; 2008 Nov;29(10):1872-7
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient.
  • BACKGROUND AND PURPOSE: Histopathologic grade of glial tumors is inversely correlated with the minimum apparent diffusion coefficient (ADC).
  • We assessed the diagnostic values of minimum ADC for preoperative grading of supratentorial astrocytomas that were diagnosed as low-grade astrocytomas on conventional MR imaging.
  • MATERIALS AND METHODS: Among 118 patients with astrocytomas (WHO grades II-IV), 16 who showed typical MR imaging findings of low-grade supratentorial astrocytomas on conventional MR imaging were included.
  • The minimum ADC value of each tumor was determined from several regions of interest in the tumor on ADC maps.
  • To assess the relationship between the minimum ADC and tumor grade, we performed the Mann-Whitney U test.
  • A receiver operating characteristic (ROC) analysis was used to determine the cutoff value of the minimum ADC that had the best combination of sensitivity and specificity for distinguishing low- and high-grade astrocytomas.
  • RESULTS: Eight of the 16 patients (50%) were confirmed as having high-grade astrocytomas (WHO grades III and IV), and the other 8 patients were confirmed as having low-grade astrocytomas (WHO grade II).
  • The median minimum ADC of the high-grade astrocytoma (1.035 x 10(-3) mm(2) .
  • sec(-1)) group was significantly lower than that of the low-grade astrocytoma group (1.19 x 10(-3) mm(2) .
  • CONCLUSION: Measuring minimum ADC can provide valuable diagnostic information for the preoperative grading of presumptive low-grade supratentorial astrocytomas.
  • [MeSH-major] Algorithms. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719036.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Muragaki Y, Chernov M, Maruyama T, Ochiai T, Taira T, Kubo O, Nakamura R, Iseki H, Hori T, Takakura K: Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate? Minim Invasive Neurosurg; 2008 Oct;51(5):275-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade glioma on stereotactic biopsy: how often is the diagnosis accurate?
  • The objective of the present study was an evaluation of the incidence and risk factors for erroneous histopathological diagnosis of low-grade glioma after stereotactic biopsy.
  • Twenty-eight tumors diagnosed as low-grade glioma after stereotactic biopsy and surgically resected thereafter were analyzed.
  • Complete diagnostic agreement in tumor typing and grading after stereotactic biopsy and surgical resection was attained in 10 cases (36%).
  • Agreement in tumor typing was marked in 16 cases (57%).
  • Overgrading of WHO grade I tumors was marked in 3 cases (11%) and undergrading of WHO grade III gliomas in 8 cases (28%).
  • Tumor undergrading was more frequent in cases with an MIB-1 index of more than 3% (P = 0.0045).
  • In conclusion, the histopathological diagnosis of low-grade glioma established after stereotactic biopsy is associated with a substantial risk of inaccuracy.
  • Tumors with low proliferative activity and mixed gliomas are especially susceptible for erroneous tumor typing.
  • Undergrading of high-grade gliomas may be suspected if the MIB-1 index in the tumor specimen constitutes more, than 3%.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Biopsy / statistics & numerical data. Brain / pathology. Brain / surgery. Child. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Mitotic Index. Neurosurgical Procedures. Observer Variation. Oligodendroglioma / pathology. Predictive Value of Tests. Reproducibility of Results. Stereotaxic Techniques / statistics & numerical data. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855292.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


45. Frenay MP, Fontaine D, Vandenbos F, Lebrun C: First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas. Eur J Neurol; 2005 Sep;12(9):685-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First-line nitrosourea-based chemotherapy in symptomatic non-resectable supratentorial pure low-grade astrocytomas.
  • At the present time, there are no proven beneficial effects of chemotherapy (CT) for the treatment of pure low-grade astrocytomas.
  • Brain radiotherapy (RT) still remains the standard treatment in order to reduce or delay tumor progression or symptoms, despite possible long-term neurologic complications.
  • We report 10 patients, with histologically proven pure low-grade fibrillary astrocytomas, to which we administered a first-line nitrosourea-based CT.
  • CT was well tolerated; all patients developed myelosuppression with 40% of grade III/IV hematotoxicity.
  • These results demonstrate that some patients with symptomatic non-resectable fibrillary low-grade astrocytomas can be treated with up-front CT to improve their neurologic status.
  • [MeSH-major] Astrocytoma / therapy. Brain Neoplasms / therapy. Drug Therapy / methods. Nitrosourea Compounds / therapeutic use
  • [MeSH-minor] Adult. Cerebral Cortex / drug effects. Cerebral Cortex / pathology. Combined Modality Therapy. Epilepsy / complications. Epilepsy / drug therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128869.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrosourea Compounds
  •  go-up   go-down


46. Faria MH, Gonçalves BP, do Patrocínio RM, de Moraes-Filho MO, Rabenhorst SH: Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status. Neuropathology; 2006 Dec;26(6):519-27
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67, topoisomerase IIalpha and c-MYC in astrocytic tumors: correlation with the histopathological grade and proliferative status.
  • Recently, the determination of the proliferative index of astrocytic tumors by different methods has been proposed as a valuable tool for tumor grading and also as a prognostic marker.
  • The aim of the present study was to evaluate the expression of cell proliferation-related proteins in human astrocytic tumors of different histopathological grades (WHO).
  • An immunohistochemical study of the Ki-67, Topoisomerase IIalpha (Topo IIalpha) and c-MYC proteins using the avidin-biotin-peroxidase method was performed in 55 astrocytomas (13 grade I, 14 grade II, 7 grade III and 21 grade IV) and five samples of non-tumor brain tissue (control group).
  • Ki-67, Topo IIalpha and c-MYC positive indices tended to increase according to malignant progression, were absent in non-tumor brain tissue and showed maximum values in high-grade astrocytomas (III and IV).
  • Ki-67 antigen detection in more than 8.0% of the tumor cells distinguished astrocytoma grade IV, while a labeling index between 1.5 and 8.0% characterized astrocytomas grade III and values below 1.5% discriminated low-grade tumors (I and II).
  • Moreover, Ki-67 antigen was found to be the best marker of cellular proliferation, and its expression predicts the grade of astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Astrocytoma / pathology. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / metabolism. Cell Division. Child. Child, Preschool. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Female. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Immunohistochemistry. Infant. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Proto-Oncogene Proteins c-myc / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17203587.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-myc; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


47. Mittelbronn M, Simon P, Löffler C, Capper D, Bunz B, Harter P, Schlaszus H, Schleich A, Tabatabai G, Goeppert B, Meyermann R, Weller M, Wischhusen J: Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol; 2007 Sep;189(1-2):50-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells.
  • To investigate HLA-E expression and immune cell infiltration in human astrocytic tumors in vivo, we analyzed normal CNS controls and astrocytomas of all WHO grades by immunohistochemistry.
  • Both, CD8(+) immune cell infiltration and HLA-E expression were significantly higher in astrocytic tumors than in normal brain.
  • Further, HLA-E expression levels and immune cell infiltration were significantly correlated in WHO grade IV glioblastomas.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. CD8-Positive T-Lymphocytes / physiology. Gene Expression Regulation, Neoplastic / physiology. Glioblastoma / metabolism. HLA Antigens / metabolism. Histocompatibility Antigens Class I / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675252.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-E antigen; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


48. Warnke PC: A 31-year-old woman with a transformed low-grade glioma. JAMA; 2010 Mar 10;303(10):967-76
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 31-year-old woman with a transformed low-grade glioma.
  • Low-grade gliomas in adults have an incidence of 0.8 to 1.2 per 100,000, and their causes are unknown.
  • Despite their histological classification as low-grade, they cannot be cured by any current treatment mode, and no class I evidence exists to guide initial treatment of these tumors.
  • The prognosis depends on age, World Health Organization (WHO) tumor grade, Karnofsky performance score, cytological type (oligodendroglioma vs astrocytoma), and, potentially, the extent of resection.
  • Low-grade tumors progress to high-grade gliomas with aggressive biological behavior at increasing frequency with advancing age.
  • Ms P is a young woman with a previously treated oligodendroglioma, WHO grade II, with loss of heterozygosity on chromosomes 1p and 19q, which at a third resection had transformed into an oligodendroglioma of WHO grade III.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20159860.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Case Reports; Clinical Conference; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Corsa P, Parisi S, Raguso A, Troiano M, Perrone A, Cossa S, Munafò T, Piombino M, Spagnoletti G, Borgia F: Temozolomide and radiotherapy as first-line treatment of high-grade gliomas. Tumori; 2006 Jul-Aug;92(4):299-305
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide and radiotherapy as first-line treatment of high-grade gliomas.
  • AIMS AND BACKGROUND: Temozolomide, a novel alkylating agent, has shown promising results in the treatment of patients with high-grade gliomas, when used as single agent as well as in combination with radiation therapy.
  • MATERIALS AND METHODS: In this report we retrospectively reviewed the clinical outcome of 128 consecutive patients with a diagnosis of high-grade gliomas referred to our Institutions from April 1994 to November 2001.
  • RESULTS: Grade 3 hematological toxicity was scored in 9% of 64 patients treated with radiotherapy and temozolomide.
  • No grade 4 hematological toxicity was reported, and the other acute side effects observed were mild or easily controlled with medications.
  • CONCLUSIONS: We report the favorable results of a schedule combining radiotherapy and temozolomide in the treatment of patients with high-grade gliomas.
  • The literature data and above all the findings of the phase III EORTC-NCIC 26981 trial suggest that actually the schedule can be used routinely in clinical practice.
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Chemotherapy, Adjuvant. Female. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tumori. 2007 Sep-Oct;93(5):526; author reply 526 [18038893.001]
  • (PMID = 17036520.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


50. Mao Y, Zhou L, Zhu W, Wang X, Yang G, Xie L, Mao X, Jin K: Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas. Front Biosci; 2007;12:2252-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative status of tumor stem cells may be correlated with malignancy grade of human astrocytomas.
  • Tumor stem cells are implicated in tumor initiation and maintenance.
  • In vivo implantation of these cells can induce tumors that phenocopy original tumors, suggesting that tumor stem cells are involved in brain carcinogenesis.
  • We found that a population of cells in human glioblastoma multiforme expressed multiple protein markers of neural stem cells including nestin, TUC-4, doublecortin and beta III-tubulin.
  • Double immunolabeling showed that a portion of doublecortin-, beta III-tubulin-, TUC-4- and nestin-positive cells express Ki67 antigen, a cell proliferation marker.
  • To investigate further whether these properties of tumor stem cells are correlated with their biological behavior, immunohistochemistry was performed on brain sections from astrocytomas of different grades using antibodies against neural stem cell markers.
  • The number of cells expressing Ki67 antigen and neural stem cell markers was increased in relation to worsening histological grade of astrocytomas, indicating that the capacity for tumor stem cell proliferation may be clinically relevant.
  • Thus, tumor stem cells in astrocytomas may be involved in carcinogenesis.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Child, Preschool. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Middle Aged. Neurons / metabolism. Stem Cells / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17127461.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG21980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


51. Ritz R, Müller M, Dietz K, Duffner F, Bornemann A, Roser F, Tatagiba M: Hypericin uptake: a prognostic marker for survival in high-grade glioma. J Clin Neurosci; 2008 Jul;15(7):778-83
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypericin uptake: a prognostic marker for survival in high-grade glioma.
  • Three patients suffered from an anaplastic astrocytoma, WHO grade III, nine had a glioblastoma, WHO grade IV.
  • [MeSH-major] Brain Neoplasms / drug therapy. Drug Resistance, Neoplasm / genetics. Glioma / drug therapy. Perylene / analogs & derivatives. Photochemotherapy / methods
  • [MeSH-minor] Adult. Aged. Astrocytoma / drug therapy. Astrocytoma / metabolism. Astrocytoma / physiopathology. Cell Line, Tumor. Cell Proliferation. Disease-Free Survival. Drug Therapy. Female. Fluorescence. Glioblastoma / drug therapy. Glioblastoma / metabolism. Glioblastoma / physiopathology. Humans. Light. Lipoproteins, LDL / metabolism. Male. Microscopy, Fluorescence / methods. Middle Aged. Models, Statistical. Predictive Value of Tests. Prognosis. Radiation-Sensitizing Agents / metabolism. Radiotherapy. Survival Rate

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Neurosci. 2009 Oct;16(10):1381-2 [19595595.001]
  • (PMID = 18394904.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Lipoproteins, LDL; 0 / Radiation-Sensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


52. Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS: Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg; 2008 Feb;108(2):227-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizure characteristics and control following resection in 332 patients with low-grade gliomas.
  • OBJECT: Seizures play an important role in the clinical presentation and postoperative quality of life of patients who undergo surgical resection of low-grade gliomas (LGGs).
  • METHODS: The authors performed a retrospective chart review of all cases involving adult patients who underwent initial surgery for LGGs at the University of California, San Francisco between 1997 and 2003.
  • Cortical location and oligodendroglioma and oligoastrocytoma subtypes were significantly more likely to be associated with seizures compared with deeper midline locations and astrocytoma, respectively (p=0.017 and 0.001, respectively; multivariate analysis).
  • For the cohort of patients that presented with seizures, 12-month outcome after surgery (Engel class) was as follows: seizure free (I), 67%; rare seizures (II), 17%; meaningful seizure improvement (III), 8%; and no improvement or worsening (IV), 9%.
  • Seizure recurrence after initial postoperative seizure control was associated with tumor progression (p=0.001).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anticonvulsants / therapeutic use. Cohort Studies. Disease Progression. Epilepsies, Partial / etiology. Epilepsies, Partial / prevention & control. Epilepsy, Complex Partial / etiology. Epilepsy, Complex Partial / prevention & control. Female. Follow-Up Studies. Humans. Male. Middle Aged. Oligodendroglioma / complications. Oligodendroglioma / surgery. Quality of Life. Recurrence. Retrospective Studies. Temporal Lobe / pathology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Seizures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Epilepsy Curr. 2009 Jul-Aug;9(4):98-100 [19693324.001]
  • (PMID = 18240916.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


53. Gimenez M, Souza VC, Izumi C, Barbieri MR, Chammas R, Oba-Shinjo SM, Uno M, Marie SK, Rosa JC: Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin. Proteomics; 2010 Aug;10(15):2812-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of low- to high-grade astrocytomas reveals an alteration of the expression level of raf kinase inhibitor protein and nucleophosmin.
  • The aim of this study was to identify differentially expressed proteins in diffuse astrocytoma grade II, anaplastic astrocytoma grade III and glioblastoma multiforme grade IV in human tumor samples and in non-neoplastic brain tissue as control using 2-DE and MS.
  • Tumor and control brain tissue dissection was guided by histological hematoxylin/eosin tissue sections to provide more than 90% of tumor cells and astrocytes.
  • Six proteins were detected as up-regulated in higher grade astrocytomas and the most important finding was nucleophosmin (NPM) (p<0.05), whereas four proteins were down-regulated, among them raf kinase inhibitor protein (RKIP) (p<0.05).
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Nuclear Proteins / genetics. Phosphatidylethanolamine Binding Protein / genetics. Proteomics
  • [MeSH-minor] Adult. Amino Acid Sequence. Brain / metabolism. Brain / pathology. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Proteins / genetics. Proteins / isolation & purification


54. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K: Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. Am J Surg Pathol; 2006 May;30(5):657-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas.
  • Distinguishing between grade II and grade III diffuse astrocytomas is important both for prognosis and for treatment decision-making.
  • We tested the relationship between pHH3 staining and tumor grade and prognosis in a retrospective series of grade II and III infiltrating astrocytomas from a single institution.
  • The pHH3 index (per 1000 cells), MIB-1 index (per 1000 cells), and number of mitoses per 10 high-power fields were determined for each of 103 cases of grade II and III diffuse astrocytomas from patients with clinical follow-up. pHH3 staining was found to be a simple and reliable method for identifying mitotic figures, allowing a true mitotic index to be determined.
  • Thus, pHH3 staining provides a simple and reliable method for quantifying proliferative potential and for the stratification of patients with diffuse astrocytomas into typical grade II and III groups.
  • These results also suggest that pHH3 staining may be a useful method in other neoplasms in which accurate determination of proliferation potential is relevant to tumor grading or clinical treatment decision-making.
  • [MeSH-major] Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Histones / metabolism. Mitotic Index
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16699322.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones; 0 / Ki-67 Antigen
  •  go-up   go-down


55. Caltabiano R, Torrisi A, Condorelli D, Albanese V, Lanzafame S: High levels of connexin 43 mRNA in high grade astrocytomas. Study of 32 cases with in situ hybridization. Acta Histochem; 2010 Nov;112(6):529-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High levels of connexin 43 mRNA in high grade astrocytomas. Study of 32 cases with in situ hybridization.
  • The aims of the research reported here were (1) to evaluate the Cx43 protein and mRNA of both low histological grade and high histological grade astrocyte tumors;.
  • (2) to evaluate if the immunohistochemistry of the Cx43 protein in astrocytomas could be correlated to histological grade, to proliferative activity (Ki67/Mib1-index) and to immunolabelling of the epidermal growth factor receptor (EGFR);.
  • This study showed that the immunohistochemical labelling of Cx43 is reduced in grade III and grade IV.
  • This study demonstrated also the persistence in high grade astrocytomas of elevated levels of Cx43 mRNA.
  • [MeSH-major] Astrocytoma / genetics. Connexin 43 / analysis. Connexin 43 / genetics. In Situ Hybridization. RNA, Messenger / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Glioblastoma / genetics. Glioblastoma / metabolism. Humans. Immunohistochemistry. Male. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier GmbH. All rights reserved.
  • (PMID = 19604543.001).
  • [ISSN] 1618-0372
  • [Journal-full-title] Acta histochemica
  • [ISO-abbreviation] Acta Histochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Connexin 43; 0 / RNA, Messenger
  •  go-up   go-down


56. Jain R, Ellika SK, Scarpace L, Schultz LR, Rock JP, Gutierrez J, Patel SC, Ewing J, Mikkelsen T: Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol; 2008 Apr;29(4):694-700
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade.
  • BACKGROUND AND PURPOSE: Glioma angiogenesis and its different hemodynamic features, which can be evaluated by using perfusion CT (PCT) imaging of the brain, have been correlated with the grade and the aggressiveness of gliomas.
  • Our hypothesis was that quantitative estimation of permeability surface area product (PS), cerebral blood volume (CBV), cerebral blood flow (CBF), and mean transit time (MTT) in astroglial brain tumors by using PCT will correlate with glioma grade.
  • High-grade gliomas will show higher PS and CBV as compared with low-grade gliomas.
  • MATERIALS AND METHODS: PCT was performed in 32 patients with previously untreated astroglial tumors (24 high-grade gliomas and 8 low-grade gliomas) by using a total acquisition time of 170 seconds.
  • RESULTS: The differences in PS, CBV, and CBF between the low- and high-grade tumor groups were statistically significant, with the low-grade group showing lower mean values than the high-grade group.
  • ROC analyses showed that both CBV (C-statistic 0.930) and PS (C-statistic 0.927) were very similar to each other in differentiating low- and high-grade gliomas and had higher predictability compared with CBF and MTT.
  • Within the high-grade group, differentiation of WHO grade III and IV gliomas was also possible by using PCT parameters, and PS showed the highest C-statistic value (0.926) for the ROC analyses in this regard.
  • CONCLUSIONS: Both PS and CBV showed strong association with glioma grading, high-grade gliomas showing higher PS and CBV as compared with low-grade gliomas.
  • Perfusion parameters, especially PS, can also be used to differentiate WHO grade III from grade IV in the high-grade tumor group.
  • [MeSH-major] Astrocytoma / radiography. Brain Neoplasms / radiography. Capillary Permeability. Cerebrovascular Circulation. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Blood Flow Velocity. Blood Volume. Contrast Media. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18202239.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


57. Liebrich M, Guo LH, Schluesener HJ, Schwab JM, Dietz K, Will BE, Meyermann R: Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors. Arch Immunol Ther Exp (Warsz); 2007 Jan-Feb;55(1):41-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-16 by tumor-associated macrophages/activated microglia in high-grade astrocytic brain tumors.
  • MATERIALS AND METHODS: Expression of IL-16 was analyzed by immunohistochemistry in human astrocytic brain tumors and the rat C6 glioblastoma tumor model.
  • IL-16 was detected in both human astrocytic brain tumors and rat C6 glioma.
  • RESULTS: Compared with human control brains, a significant increase in the percentages of parenchymal IL-16+ macrophages/microglia was observed already in grade II astrocytomas, indicating that IL-16+ immunostaining could be a descriptor of a macrophage/microglia subset in astrocytic brain tumors.
  • A further increase was observed at the transition from grade II to III astrocytomas.
  • This increase in IL-16 immunoreactivity correlated with WHO grades of human astrocytic brain tumors.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Glioblastoma / immunology. Interleukin-16 / biosynthesis. Macrophages / immunology. Microglia / immunology
  • [MeSH-minor] Adult. Aged. Animals. Cell Line, Tumor. Female. Humans. Inflammation Mediators / metabolism. Male. Middle Aged. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 May 1;164(9):4429-32 [10779741.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):752-3 [15944689.001]
  • [Cites] Lancet. 2001 Feb 17;357(9255):539-45 [11229684.001]
  • [Cites] Int J Dev Neurosci. 2001 Feb;19(1):93-100 [11226758.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):249-55 [11307625.001]
  • [Cites] Microsc Res Tech. 2001 Jul 15;54(2):106-13 [11455617.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):141-7 [11859968.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):947-56 [12213723.001]
  • [Cites] Glia. 2002 Nov;40(2):252-9 [12379912.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] J Neurosci. 2003 Jun 1;23(11):4410-9 [12805281.001]
  • [Cites] J Neuroimmunol. 2004 Jan;146(1-2):39-45 [14698845.001]
  • [Cites] Glia. 2004 Jan 15;45(2):208-12 [14730714.001]
  • [Cites] J Leukoc Biol. 2004 Mar;75(3):388-97 [14612429.001]
  • [Cites] J Immunol. 1982 Jun;128(6):2563-8 [7042840.001]
  • [Cites] Semin Oncol. 1994 Apr;21(2):149-61 [8153661.001]
  • [Cites] Nature. 1996 May 2;381(6577):29-30 [8609983.001]
  • [Cites] J Neurosci Res. 1996 Jun 15;44(6):606-11 [8794952.001]
  • [Cites] Glia. 1997 Aug;20(4):365-72 [9262239.001]
  • [Cites] Nature. 1998 Apr 30;392(6679):936-41 [9582076.001]
  • [Cites] Int Rev Immunol. 1998;16(5-6):523-40 [9646175.001]
  • [Cites] Prog Neurobiol. 1999 Jun;58(3):233-47 [10341362.001]
  • [Cites] Cancer Cell. 2005 Mar;7(3):211-7 [15766659.001]
  • [Cites] Acta Neuropathol. 2000 Sep;100(3):313-22 [10965802.001]
  • (PMID = 17221335.001).
  • [ISSN] 0004-069X
  • [Journal-full-title] Archivum immunologiae et therapiae experimentalis
  • [ISO-abbreviation] Arch. Immunol. Ther. Exp. (Warsz.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Inflammation Mediators; 0 / Interleukin-16
  • [Other-IDs] NLM/ PMC3234149
  •  go-up   go-down


58. El Andaloussi A, Lesniak MS: CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol; 2007 Jun;83(2):145-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas.
  • In this study, we investigated the correlation between FoxP3 and HO-1 expression in patients with various grades of astrocytoma (WHO grade II-IV).
  • Using qualitative and quantitative reverse transcriptase-polymerase chain reaction and quantitative flow cytometry analyses, we analyzed FoxP3 and HO-1 expression in 19 patients with different grades of astrocytoma.
  • We observed the highest level of FoxP3 expression in patients with grade IV tumors (11.54 +/- 1.95%) vs. grade III (6.74 +/- 0.19%) or grade II (2.53 +/- 0.11%) (P < 0.05).
  • Moreover, in grade IV tumors, the frequency of HO-1 mRNA expression in CD4+ CD25+ cells was 11.8 +/- 2.45% vs. 7.42 +/- 0.31% in grade III and 2.33 +/- 0.12% in grade II.
  • Tumor infiltrating Treg stained positively with anti-HO-1 antibody.
  • [MeSH-major] Brain Neoplasms / immunology. Glioblastoma / immunology. Heme Oxygenase-1 / metabolism. Lymphocytes, Tumor-Infiltrating / metabolism. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD4 / metabolism. Child, Preschool. Female. Forkhead Transcription Factors / genetics. Forkhead Transcription Factors / metabolism. Gene Expression Regulation. Gene Expression Regulation, Neoplastic / immunology. Humans. Interleukin-2 Receptor alpha Subunit / metabolism. Male. Middle Aged. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 4;306(3):701-5 [12810075.001]
  • [Cites] J Biol Chem. 1997 Feb 28;272(9):5375-81 [9038135.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):1220-6 [14707100.001]
  • [Cites] Neurosci Lett. 1995 Oct 20;199(2):127-30 [8584240.001]
  • [Cites] Am J Reprod Immunol. 2005 Dec;54(6):369-77 [16305662.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):234-43 [16723631.001]
  • [Cites] Cancer Sci. 2005 Aug;96(8):527-33 [16108835.001]
  • [Cites] Mini Rev Med Chem. 2006 May;6(5):509-13 [16719824.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):913-20 [15714205.001]
  • [Cites] J Neurochem. 1992 Mar;58(3):1140-9 [1737989.001]
  • [Cites] Ann Neurol. 1995 Jun;37(6):758-68 [7778849.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1667-75 [8833917.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Jun;38(2):251-9 [8793113.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12 ):1945-54 [10471043.001]
  • [Cites] J Biol Chem. 1989 Jan 15;264(2):1323-8 [2910857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Aug;84(16):5918-22 [3475708.001]
  • [Cites] FASEB J. 1988 Jul;2(10 ):2557-68 [3290025.001]
  • [Cites] Br J Cancer. 2003 Mar 24;88(6):902-9 [12644828.001]
  • [Cites] Brain Res. 2000 Nov 3;882(1-2):1-8 [11056178.001]
  • [Cites] Semin Cancer Biol. 2006 Feb;16(1):73-9 [16140545.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Jul 5;224(1):153-8 [8694803.001]
  • [Cites] J Pathol. 2000 Apr;190(5):627-34 [10727990.001]
  • [Cites] Immunol Res. 2005;32(1-3):155-68 [16106066.001]
  • [Cites] Cancer Immunol Immunother. 2005 Dec;54(12):1153-61 [15868167.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4744-51 [15067050.001]
  • [Cites] Brain Res Mol Brain Res. 1996 Apr;37(1-2):201-8 [8738152.001]
  • [Cites] Clin Cancer Res. 1999 May;5(5):1107-13 [10353745.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):606-12 [12576425.001]
  • [Cites] Free Radic Biol Med. 2004 Apr 1;36(7):858-71 [15019971.001]
  • [Cites] Transpl Immunol. 1998 Jun;6(2):84-93 [9777696.001]
  • [Cites] Semin Cancer Biol. 2006 Apr;16(2):106-14 [16423537.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Feb 25;327(4):1066-71 [15652505.001]
  • [Cites] J Neurochem. 1999 Mar;72 (3):1187-203 [10037492.001]
  • [Cites] Science. 1987 Feb 27;235(4792):1043-6 [3029864.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):430-7 [16961139.001]
  • (PMID = 17216339.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Interleukin-2 Receptor alpha Subunit; 0 / RNA, Messenger; EC 1.14.14.18 / Heme Oxygenase-1
  •  go-up   go-down


59. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer; 2005 Feb 15;103(4):802-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
  • BACKGROUND: Anaplastic oligodendroglioma (OD) tumors, especially those with the combined loss of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), are sensitive to chemotherapy.
  • Only limited data are available on the role of chemotherapy in low-grade OD.
  • The authors retrospectively studied the outcome of the procarbazine, lomustine, and vincristine (PCV) chemotherapy regimen in a group of 16 patients with newly diagnosed OD and 5 patients with recurrent low-grade OD.
  • Several patients showed a signficant clinical improvement despite only a modest improvement of the tumor on the MRI scans.
  • A Phase III trial should be initiated to compare radiotherapy with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. Procarbazine / therapeutic use. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15637687.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


60. Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ: In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol; 2010 Mar;97(1):11-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines.
  • This study's objective was to utilise microdialysis to monitor levels of glucose, lactate, pyruvate, glutamate and glycerol in patients following surgery for intrinsic brain tumours, and to assess the concentration of growth factors, cytokines and other proteins involved in the pathogenesis of high-grade gliomas in vivo.
  • Eight patients with suspected high-grade gliomas were studied.
  • Histology demonstrated WHO IV glioblastoma in five cases, WHO III anaplastic astrocytoma in two cases, and one cerebral lymphoma.
  • In the high-grade gliomas (WHO IV and III), tumour margin microdialysates consistently showed significantly lower glucose, higher lactate/pyruvate (L/P) ratio, higher glutamate and higher glycerol, relative to peritumour microdialysates (P < 0.05).
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents, Hormonal / pharmacology. Dexamethasone / pharmacology. Female. Glucose / metabolism. Glutamic Acid / metabolism. Glycerol / metabolism. Humans. Lactic Acid / metabolism. Male. Matrix Metalloproteinase 9 / metabolism. Microdialysis / methods. Middle Aged. Pyruvic Acid / metabolism. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. GLYCERIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1999;886:236-9 [10667228.001]
  • [Cites] Clin Cancer Res. 2006 Oct 1;12 (19):5698-704 [17020973.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):105-12 [15696970.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Neuro Oncol. 2005 Apr;7(2):122-33 [15831231.001]
  • [Cites] Nature. 1985 Jan 10-18;313(5998):144-7 [2981413.001]
  • [Cites] J Cell Sci. 1997 Oct;110 ( Pt 19):2473-82 [9410885.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Eur J Clin Pharmacol. 1983;24(1):103-8 [6832191.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):208-19 [10935475.001]
  • [Cites] Physiol Meas. 2005 Aug;26(4):423-8 [15886437.001]
  • [Cites] Curr Med Chem. 2007;14(14):1525-37 [17584061.001]
  • [Cites] J Neuroimmunol. 1997 Sep;78(1-2):152-61 [9307240.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):464-73 [11235952.001]
  • [Cites] Science. 2006 May 26;312(5777):1158-9 [16728625.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2894-901 [12231534.001]
  • [Cites] Int J Cancer. 1997 Jun 11;71(6):1066-76 [9185713.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):300-5 [9950501.001]
  • [Cites] J Physiol. 2007 May 1;580(Pt.3):937-49 [17317742.001]
  • [Cites] J Clin Neurosci. 2005 Nov;12(8):930-3 [16326273.001]
  • [Cites] Br J Neurosurg. 2007 Apr;21(2):204-9 [17453790.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Neurooncol. 2005 Feb;71(3):287-93 [15735919.001]
  • [Cites] Biochim Biophys Acta. 2000 Mar 7;1477(1-2):267-83 [10708863.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3196-8 [8764105.001]
  • [Cites] J Neurooncol. 2006 Dec;80(3):285-93 [16773220.001]
  • [Cites] J Neurooncol. 2009 Jan;91(1):51-8 [18787762.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):39-45 [14756439.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):72-80 [1727172.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6683-8 [2208133.001]
  • [Cites] Bull Schweiz Akad Med Wiss. 1974 Jul;30(1-3):44-55 [4371656.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):865-74 [3033172.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):151-60 [12622454.001]
  • [Cites] Lancet. 1993 Jun 26;341(8861):1607-10 [8099987.001]
  • [Cites] Brain Pathol. 1990 Sep;1(1):12-8 [1669688.001]
  • [Cites] Acta Neurochir (Wien). 1993;121(3-4):199-205 [8512018.001]
  • [Cites] Eur J Anaesthesiol. 1996 May;13(3):269-78 [8737118.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Oct;47(10):1087-90 [6502166.001]
  • [Cites] J Neurotrauma. 2007 Oct;24(10):1545-57 [17970618.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Int J Cancer. 2005 Jun 10;115(2):202-13 [15688401.001]
  • [Cites] Brain Tumor Pathol. 2001;18(1):13-21 [11517969.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Oct;84(19):6899-903 [3477813.001]
  • [Cites] Eur J Pharmacol. 2008 Sep 28;593(1-3):1-9 [18652821.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):11-22 [10930095.001]
  • [Cites] Radiology. 1990 Sep;176(3):791-9 [2389038.001]
  • [Cites] Neoplasia. 2007 Sep;9(9):777-87 [17898873.001]
  • [Cites] Acta Neurochir (Wien). 2009 Jan;151(1):51-61; discussion 61 [19099177.001]
  • [Cites] Dev Biol. 1974 Dec;41(2):255-66 [4548877.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2576-82 [12855633.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):657-64 [7674016.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S37-43 [11684441.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] J Neuroimmunol. 1994 Mar;50(2):187-94 [8120140.001]
  • [Cites] J Neurosurg. 2007 May;106(5):820-5 [17542525.001]
  • [Cites] Nature. 1974 Aug 2;250(465):422-4 [4368539.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):453-9 [9467557.001]
  • [Cites] Annu Rev Biochem. 1977;46:765-95 [197882.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Ann Neurol. 1992 Mar;31(3):319-27 [1637139.001]
  • [Cites] Acta Neurochir (Wien). 1992;114(1-2):8-11 [1561943.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Mar;278(3):E413-20 [10710495.001]
  • [Cites] J Neurosurg. 2000 Jul;93(1):37-43 [10883903.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Oct;27(9):1969-74 [17032877.001]
  • [Cites] J Neurosurg. 1996 Apr;84(4):606-16 [8613852.001]
  • [Cites] Biomed Pharmacother. 2005 Aug;59(7):359-64 [16084059.001]
  • [Cites] Brain Res Bull. 2000 Jan 1;51(1):29-34 [10654577.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] Cancer Res. 1991 Apr 15;51(8):2164-72 [2009534.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2008 Jul-Aug;79(1-2):59-65 [18762411.001]
  • [Cites] Biol Psychiatry. 1997 Mar 1;41(5):574-84 [9046990.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):55-63 [11437402.001]
  • [Cites] Neurosurgery. 2005 Jun;56(6):1264-8; discussion 1268-70 [15918942.001]
  • (PMID = 19714445.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0600986; United Kingdom / Medical Research Council / / G9439390; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Cytokines; 0 / Intercellular Signaling Peptides and Proteins; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; 33X04XA5AT / Lactic Acid; 3KX376GY7L / Glutamic Acid; 7S5I7G3JQL / Dexamethasone; 8558G7RUTR / Pyruvic Acid; EC 3.4.24.35 / Matrix Metalloproteinase 9; IY9XDZ35W2 / Glucose; PDC6A3C0OX / Glycerol
  •  go-up   go-down


61. Maire JP, Huchet A, Catry-Thomas I: [Radiotherapy of adult glial tumors: new developments and perspectives]. Rev Neurol (Paris); 2008 Jun-Jul;164(6-7):531-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiotherapy of adult glial tumors: new developments and perspectives].
  • Adult gliomas (WHO grade II, III and IV) are heterogeneous primitive brain tumors.
  • Median survivals are different with regard to the tumor grade.
  • [MeSH-minor] Adult. Astrocytoma / radiotherapy. Glioblastoma / radiotherapy. Humans. Medical Oncology / trends. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565351.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 89
  •  go-up   go-down


62. Balzarotti M, Fontana F, Marras C, Boiardi A, Croci D, Ciusani E, Salmaggi A: In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res; 2006;16(5):245-50
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas.
  • In the last years results of preclinical and clinical studies have suggested that LMWH may be able to inhibit cell growth, cell invasion, and angiogenesis, which are key mechanisms involved in tumor progression, possibly influencing favorable clinical outcome in at least a proportion of cancer patients.
  • In this work we investigated the effect of LMWH (enoxaparin) on cell growth and cell invasion in primary cell cultures obtained from high-grade glioma specimens: 5 anaplastic astrocytoma (AA) and 13 glioblastoma multiforme (GBM).
  • A significant decrease in tumor cell growth was observed after treatment with 10 U/ml (-21%; p = 0.001) and 100 U/ml (-26%; p < 0.001); tumor cells from AA (grade III;.
  • WHO) were more affected by LMWH treatment compared to cell lines from GBM (grade IV; WHO).
  • In conclusion, our results confirm the antineoplastic effect of LMWH, suggesting a potential direct role on tumor cell growth in high grade gliomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Apoptosis / drug effects. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Gene Expression Regulation, Neoplastic / drug effects. Gene Expression Regulation, Neoplastic / genetics. Humans. Male. Middle Aged. Molecular Weight. Neoplasm Invasiveness. Receptor, PAR-1 / biosynthesis. Receptor, PAR-1 / drug effects. Receptor, PAR-1 / genetics. Sensitivity and Specificity. Structure-Activity Relationship. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17294805.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enoxaparin; 0 / Receptor, PAR-1
  •  go-up   go-down


63. Bauer R, Dobesberger J, Unterhofer C, Unterberger I, Walser G, Bauer G, Trinka E, Ortler M: Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy. Acta Neurochir (Wien); 2007 Dec;149(12):1211-6; discussion 1216-7
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adult patients with temporal lobe tumours and medically refractory focal epilepsy.
  • Among these, 14 adult patients exhibited temporal lobe neoplasms associated with TLE.
  • One patient with an astrocytoma grade III underwent a second and third operation for recurrent disease.
  • Histological results: Astrocytoma 5 patients, ganglioglioma/gangliocytoma 5, oligodendroglioma 2, ependymoma 1 and dysembryoplastic neuroepithelial tumour (DNET) 1.
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / surgery. Electroencephalography. Ependymoma / surgery. Female. Follow-Up Studies. Ganglioglioma. Ganglioneuroma. Hemianopsia / etiology. Humans. Male. Middle Aged. Neuroectodermal Tumors, Primitive / surgery. Neurologic Examination. Oligodendroglioma / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940725.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


64. Blumenthal DT, Rankin C, Eyre HJ, Livingston RB, Spence AM, Stelzer KJ, Rushing EJ, Berger MS, Rivkin SE, Cohn AL, Petersdorf SH: External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial. Cancer; 2008 Aug 1;113(3):559-65
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] External beam irradiation and the combination of cisplatin and carmustine followed by carmustine alone for the treatment of high-grade glioma: a phase 2 Southwest Oncology Group trial.
  • BACKGROUND: The poor prognosis reported for patients with high-grade glial neoplasms indicates a need for the development of multimodality therapeutic approaches.
  • METHODS: SWOG 9016 study included 59 eligible patients with grade III or IV astrocytoma who received radiotherapy concurrently with carmustine/cisplatin chemotherapy.
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy, Conformal / methods. Southwestern United States. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society
  • (PMID = 18521920.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA038926
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U68WG3173Y / Carmustine
  •  go-up   go-down


65. Opstad KS, Wright AJ, Bell BA, Griffiths JR, Howe FA: Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas. J Magn Reson Imaging; 2010 Feb;31(2):289-97
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlations between in vivo (1)H MRS and ex vivo (1)H HRMAS metabolite measurements in adult human gliomas.
  • PURPOSE: To assess how accurately ex vivo high-resolution magic angle spinning (HRMAS) proton magnetic resonance spectroscopy ((1)H MRS) from small biopsy tissues relate to in vivo (1)H MRS (from larger tumor volumes) in human astrocytomas.
  • MATERIALS AND METHODS: In vivo (PRESS, TE = 30 msec) and ex vivo (presaturation) (1)H spectra of 17 human astrocytomas (4 grade II, 1 grade III and 12 glioblastomas) were quantified using LCModel.
  • Concentrations of 11 metabolites and 2 lipid/macromolecules were retrospectively compared, with histogram analysis of the in vivo MRI data used to evaluate tumor heterogeneity.
  • CONCLUSION: Within defined limitations, ex vivo astrocytoma biopsy HRMAS (1)H spectra have similar metabolic profiles to that obtained in vivo and therefore detailed ex vivo characterization of glioma biopsies can directly relate to the original tumor.
  • [MeSH-major] Algorithms. Astrocytoma / diagnosis. Astrocytoma / metabolism. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20099340.001).
  • [ISSN] 1522-2586
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1459/A2592
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protons
  •  go-up   go-down


66. Huang L, Jiang T, Yuan F, Li GL, Cui Y, Liu EZ, Wang ZC: Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study. Neuropathol Appl Neurobiol; 2009 Aug;35(4):367-79
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of chromosomes 1p and 19q status and expressions of O6-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization (WHO) grades II and III: a clinicopathological study.
  • AIMS: The objective of the present study was to verify the correlation of chromosomes 1p and 19q status and expressions of O(6)-methylguanine DNA methyltransferase (MGMT), p53 and Ki-67 in diffuse gliomas of World Health Organization grades II and III.
  • RESULTS: Loss of heterozygosity (LOH) on 1p, combined LOH on 1p and 19q, low MGMT expression and high Ki-67 expression were associated with oligodendroglial tumours, whereas high p53 expression was associated with astrocytic and mixed tumours.
  • LOH on 1p and low MGMT expression were associated with grade II oligodendroglial tumours, whereas high expressions of p53 and Ki-67 were associated with grade III oligodendroglial tumours.
  • In addition, high Ki-67 expression was associated with grade III astrocytomas.
  • CONCLUSIONS: The present study revealed significant interrelationships of the investigated molecular alterations and clinicopathological characteristics in diffuse gliomas of World Health Organization grades II and III, which support a promising role of molecular markers in the diagnostic assessment of these neoplasms.
  • [MeSH-major] Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Glioma / genetics. Ki-67 Antigen / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Child. Female. Gene Expression. Humans. Loss of Heterozygosity. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / genetics. Oligodendroglioma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19019173.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


67. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, Howe FA: Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers. Mol Cancer; 2010 Mar 23;9:66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour biomarkers.
  • RESULTS: 1D and 2D 1H HRMAS NMR was used to determine that 29 small molecule metabolites, along with 8 macromolecule signals, account for the majority of the HRMAS spectrum of the main types of brain tumour (astrocytoma grade II, grade III gliomas, glioblastomas, metastases, meningiomas and also lymphomas).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Magnetic Resonance Spectroscopy / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):3125-32 [10652601.001]
  • [Cites] NMR Biomed. 2000 May;13(3):129-53 [10861994.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Oct;21(9):1645-9 [11039343.001]
  • [Cites] Neuro Oncol. 2000 Apr;2(2):87-95 [11303625.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Eur Radiol. 2002 Feb;12(2):329-40 [11870430.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1890-7 [11912170.001]
  • [Cites] J Neurosurg. 2002 Jun;96(6):1023-31 [12066902.001]
  • [Cites] NMR Biomed. 2002 Aug;15(5):327-37 [12203224.001]
  • [Cites] NMR Biomed. 2002 Oct;15(6):375-84 [12357551.001]
  • [Cites] Magn Reson Med. 2003 Apr;49(4):632-7 [12652533.001]
  • [Cites] NMR Biomed. 2003 May;16(3):123-31 [12884355.001]
  • [Cites] Magn Reson Imaging. 2003 Jul;21(6):663-72 [12915198.001]
  • [Cites] J Biol Chem. 2003 Nov 14;278(46):45915-23 [12954643.001]
  • [Cites] Magn Reson Med. 2004 Feb;51(2):225-9 [14755644.001]
  • [Cites] NMR Biomed. 2004 Jun;17(4):191-205 [15229932.001]
  • [Cites] J Magn Reson Imaging. 2004 Aug;20(2):187-92 [15269942.001]
  • [Cites] Magn Reson Med. 1992 Mar;24(1):123-36 [1556919.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jun;33(6):350-9 [7689180.001]
  • [Cites] Magn Reson Med. 1993 Dec;30(6):672-9 [8139448.001]
  • [Cites] J Neurochem. 1994 Oct;63(4):1538-43 [7931308.001]
  • [Cites] NMR Biomed. 1995 Sep;8(6):253-64 [8732181.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6408-13 [9177231.001]
  • [Cites] NMR Biomed. 1997 Jan;10(1):2-12 [9251109.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1997 Jul;43(5):659-73 [9298589.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1825-32 [9581820.001]
  • [Cites] J Neurochem. 1998 Aug;71(2):827-32 [9681475.001]
  • [Cites] J Magn Reson. 1999 Nov;141(1):104-20 [10527748.001]
  • [Cites] Magn Reson Med. 2005 Jan;53(1):41-8 [15690501.001]
  • [Cites] NMR Biomed. 2005 Oct;18(6):371-82 [15959923.001]
  • [Cites] Eur J Radiol. 2006 Jun;58(3):394-403 [16527438.001]
  • [Cites] NMR Biomed. 2006 Jun;19(4):411-34 [16763971.001]
  • [Cites] Int J Mol Med. 2006 Nov;18(5):859-69 [17016616.001]
  • [Cites] Magn Reson Med. 2006 Dec;56(6):1211-9 [17029227.001]
  • [Cites] Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6 [17202168.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D402-8 [17984079.001]
  • [Cites] Magn Reson Med. 2008 Jun;59(6):1266-73 [18506844.001]
  • [Cites] Exp Neurol. 2008 Aug;212(2):377-85 [18538323.001]
  • [Cites] NMR Biomed. 2008 Aug;21(7):677-85 [18186027.001]
  • [Cites] Magn Reson Med. 2008 Nov;60(5):1237-42 [18836999.001]
  • [Cites] Eur Radiol. 2008 Dec;18(12):2901-11 [18641997.001]
  • [Cites] NMR Biomed. 2008 Nov;21(10):1138-47 [18666093.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(Database issue):D603-10 [18953024.001]
  • [Cites] NMR Biomed. 2009 Feb;22(2):213-9 [19067434.001]
  • [Cites] Acta Radiol. 2009 Mar;50(2):217-25 [19096950.001]
  • [Cites] Mol Cancer. 2009;8:6 [19208232.001]
  • [Cites] Neurotherapeutics. 2009 Jul;6(3):598-603 [19560748.001]
  • [Cites] NMR Biomed. 2009 Jul;22(6):629-37 [19322812.001]
  • [Cites] J Magn Reson Imaging. 2010 Feb;31(2):289-97 [20099340.001]
  • (PMID = 20331867.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601327
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2858738
  •  go-up   go-down


68. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann C, von Deimling A: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol; 2010 Jan;20(1):245-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterozygous point mutations of isocitrate dehydrogenase (IDH)1 codon 132 are frequent in grade II and III gliomas.
  • Intriguing is the ability of mIDH1R132H to detect single infiltrating tumor cells.
  • The very high frequency and the distribution of this mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma World Health Organization (WHO) grade II from pilocytic astrocytoma or ependymoma.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / enzymology. Brain Neoplasms / genetics. Ependymoma / genetics. Glioma / enzymology. Glioma / genetics. Isocitrate Dehydrogenase / genetics. Isocitrate Dehydrogenase / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigen-Antibody Reactions. Blotting, Western. Child. Child, Preschool. Cloning, Molecular. DNA, Neoplasm / biosynthesis. DNA, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Mutation / genetics. Mutation / physiology. Protein Biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19903171.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.42. / IDH1 protein, human
  •  go-up   go-down


69. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A: Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol; 2010 Dec;120(6):707-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
  • WHO grading of human brain tumors extends beyond a strictly histological grading system by providing a basis predictive for the clinical behavior of the respective neoplasm.
  • For example, patients with glioblastoma WHO grade IV usually show a less favorable clinical course and receive more aggressive first-line treatment than patients with anaplastic astrocytoma WHO grade III.
  • Here we provide evidence that the IDH1 status is more prognostic for overall survival than standard histological criteria that differentiate high-grade astrocytomas.
  • We sequenced the isocitrate dehydrogenase 1 gene (IDH1) at codon 132 in 382 patients with anaplastic astrocytoma and glioblastoma from the NOA-04 trial and from a prospective translational cohort study of the German Glioma Network.
  • Patients with anaplastic astrocytomas carried IDH1 mutations in 60%, and patients with glioblastomas in 7.2%.
  • The sequence from more favorable to poorer outcome was (1) anaplastic astrocytoma with IDH1 mutation, (2) glioblastoma with IDH1 mutation, (3) anaplastic astrocytoma without IDH1 mutation and (4) glioblastoma without IDH1 mutation (p < 0.0001).
  • In this combined set of anaplastic astrocytomas and glioblastomas both, IDH1 mutation and IDH1 expression status were of greater prognostic relevance than histological diagnosis according to the current WHO classification system.
  • We propose to complement the current WHO classification and grading of high-grade astrocytic gliomas by the IDH1 mutation status and to use this combined histological and molecular classification in future clinical trials.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Astrocytoma / diagnosis. Astrocytoma / genetics. Astrocytoma / pathology. Cohort Studies. Female. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Young Adult


70. Samaras V, Piperi C, Levidou G, Zisakis A, Kavantzas N, Themistocleous MS, Boviatsis EI, Barbatis C, Lea RW, Kalofoutis A, Korkolopoulou P: Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Hum Immunol; 2009 Jun;70(6):391-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • IL-6- and IL-8-secreting peripheral blood monocytes (PBMCs) were evaluated in 17 glioblastoma (WHO grade IV), 5 anaplastic astrocytoma (WHO grade III), and 6 diffuse astrocytoma patients (WHO grade II), in parallel with 23 healthy controls using enzyme-linked immunosorbent spot (ELISPOT) assay.
  • The IL-8 expression was assessed immunohistochemically in patients' tumor tissue sections and correlated with the expression of COX-2, VEGF, IL-6, and microvessel morphometry (assessed using CD34 antibody).
  • IL-8 immunoreactivity was detected in malignant cells or macrophages in perivascular areas and in pseudopalisading cells around necrosis and was positively correlated with histological grade (p = 0.0175) and tumor necrosis (p = 0.0793).
  • The coordinate expression and topographical relationship of IL-6, IL-8, COX-2, and VEGF in the same tumor areas (e.g., perinecrotic areas) attest to their intimate liaison in terms of cancer-induced angiogenesis, which is probably secondary to the induction of multiple interdependent molecular pathways.
  • Moreover, our study seems to be the first attempt to link IL-8 expression by tumor cells with histological grade, implicating its potent role in gliomagenesis.
  • [MeSH-major] Astrocytoma / immunology. Brain Neoplasms / immunology. Cyclooxygenase 2 / immunology. Microvessels / immunology. Vascular Endothelial Growth Factor A / immunology
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / immunology. Female. Humans. Interleukin-6 / immunology. Interleukin-8 / immunology. Leukocytes, Mononuclear / immunology. Male. Middle Aged. Neovascularization, Pathologic / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332096.001).
  • [ISSN] 1879-1166
  • [Journal-full-title] Human immunology
  • [ISO-abbreviation] Hum. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Interleukin-6; 0 / Interleukin-8; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


71. Zhao ZX, Lan K, Xiao JH, Zhang Y, Xu P, Jia L, He M: A new method to classify pathologic grades of astrocytomas based on magnetic resonance imaging appearances. Neurol India; 2010 Sep-Oct;58(5):685-90
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Astrocytoma is the most common neuroepithelial neoplasm, and its grading greatly affects treatment and prognosis.
  • OBJECTIVE: According to relevant factors of astrocytoma, this study developed a support vector machine (SVM) model to predict the astrocytoma grades and compared the SVM prediction with the clinician's diagnostic performance.
  • PATIENTS AND METHODS: Patients were recruited from a cohort of astrocytoma patients in our hospital between January 2008 and April 2009.
  • Among all astrocytoma patients, nine had grade I, 25 had grade II, 12 had grade III, and 60 had grade IV astrocytoma.
  • The clinician also predicted the grade of astrocytoma.
  • According to the two prediction methods above, the areas under receiving operating characteristics (ROC) curves to discriminate low- and high-grade groups, accuracies of high-grade grouping, overall accuracy, and overall kappa values were compared.
  • The diagnostic performance of SVM is significantly better than clinician performance, with the exception of the low-grade group.
  • CONCLUSIONS: The SVM model can provide useful information to help clinicians improve diagnostic performance when predicting astrocytoma grade based on MR images.
  • [MeSH-major] Astrocytoma / classification. Astrocytoma / diagnosis. Brain Neoplasms / classification. Brain Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Databases, Factual / statistics & numerical data. Female. Humans. Male. Middle Aged. Models, Statistical. ROC Curve. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21045488.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


72. Nakamura M, Ishii K, Watanabe K, Tsuji T, Takaishi H, Matsumoto M, Toyama Y, Chiba K: Surgical treatment of intramedullary spinal cord tumors: prognosis and complications. Spinal Cord; 2008 Apr;46(4):282-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We reviewed 68 cases of intramedullary tumors (ependymoma, 33; astrocytoma, 23; hemangioblastoma, 12), treated surgically between 1994 and 2003.
  • The tumor malignancy grade according to the WHO classification was astrocytoma grade I, 3; grade II, 8 (low-grade: 11 cases); grade III, 10; grade IV, 2 (high-grade: 12 cases).
  • All ependymomas were grade II.
  • Approximately 50% of low-grade astrocytomas could be totally excised with favorable survival outcomes, suggesting that total excision should be attempted for low-grade astrocytomas.
  • However, total excision of high-grade tumors was difficult and the functional outcomes were poor.
  • Cordotomy should be considered in patients with a thoracic high-grade astrocytoma.
  • [MeSH-major] Astrocytoma / surgery. Ependymoma / surgery. Hemangioblastoma / surgery. Spinal Cord Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Cervical Vertebrae. Child. Child, Preschool. Cohort Studies. Female. Humans. Male. Middle Aged. Postoperative Complications. Retrospective Studies. Survival Rate. Thoracic Vertebrae. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909556.001).
  • [ISSN] 1362-4393
  • [Journal-full-title] Spinal cord
  • [ISO-abbreviation] Spinal Cord
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Khan MK, Hunter GK, Vogelbaum M, Suh JH, Chao ST: Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. Indian J Cancer; 2009 Apr-Jun;46(2):96-107
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the 18,820 new cases of primary central nervous system (CNS) tumors diagnosed annually in the United States, gliomas account for over 60% with 30-40% of them being glioblastoma multiforme (GBM), 10% being anaplastic astrocytoma (AA), and 10% being low grade gliomas (LGGs).
  • Of all adult primary CNS tumors, GBM is the most common and the most malignant with about 7,000 to 8,000 new cases annually in the United States.
  • Common to these approaches is the use of adjuvant radiation therapy, even as surgery alone, with or without chemotherapy, may be the mainstay for some lower grade and low-risk gliomas.
  • Specifically, the database is searched using the following keywords, with various combinations: glioma, low-grade, anaplastic, astrocytoma, oligodendroglioma, oligoastrocytoma, glioblastoma multiforme, chemotherapy, radiation, new concepts, phase III, MGMT, CDX-110 (Celldex), temozolomide, 1p/19q deletion, and bevacizumab.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Astrocytoma / drug therapy. Astrocytoma / radiotherapy. Astrocytoma / therapy. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346643.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 64
  •  go-up   go-down


74. Moulding HD, Friedman DP, Curtis M, Kenyon L, Flanders AE, Paek SH, Andrews DW: Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis. J Magn Reson Imaging; 2008 Dec;28(6):1311-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Revisiting anaplastic astrocytomas I: an expansive growth pattern is associated with a better prognosis.
  • PURPOSE: To study whether anaplastic astrocytomas that are nonenhancing and/or well-circumscribed (expansive) are associated with a better prognosis.
  • MATERIALS AND METHODS: We retrospectively identified 59 patients with pathologically confirmed World Health Organizaiton (WHO) grade III anaplastic astrocytoma who underwent craniotomy at our institution from 1995 through 2006.
  • A multivariate (Cox proportional hazards) analysis showed that patient age and expansive tumor phenotype affected outcome, whereas RPA class, enhancement, and GTR did not.
  • CONCLUSION: Circumscribed growth in histologically proven anaplastic astrocytoma, which has not been emphasized in past studies, has a considerable survival advantage.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Chi-Square Distribution. Contrast Media. Craniotomy. Female. Gadolinium DTPA. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Statistics, Nonparametric. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 19025897.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


75. Compostella A, Tosoni A, Blatt V, Franceschi E, Brandes AA: Prognostic factors for anaplastic astrocytomas. J Neurooncol; 2007 Feb;81(3):295-303
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for anaplastic astrocytomas.
  • Anaplastic astrocytomas (WHO grade III) constitute about 10% of all gliomas.
  • Definitive data on predictive and prognostic factors are lacking for these neoplasms that are considered the most enigmatic entity among the whole spectrum of astrocytic tumors because of their unclear biologic behavior and variable clinical outcome.
  • Currently, only few factors have been identified as useful for prognosis of anaplastic astrocytoma: age and Karnofsky Performance Status.
  • Potential prognostic biomarkers concern tumor suppressor genes on chromosome 9q that are involved in the RB1 pathway; PTEN, the PI3k/Akt/p70s6k cascade, survivin gene, Formylpeptide receptor, minichromosome maintenance protein 3 and genes on chromosome 7.
  • The state of the art pictured here underlie the recent interest on gene expression profile to identify aberrations useful to understand the biologic behavior of astrocytic tumors.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Gene Expression Profiling. Humans. Karnofsky Performance Status. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1988 Nov 15;62(10):2152-65 [3179928.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1926-33 [15143086.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):213-6 [16365177.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):85-9 [15690121.001]
  • [Cites] Cancer. 1996 Mar 15;77(6):1161-6 [8635139.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10 (15):4933-8 [15297393.001]
  • [Cites] Neurosurgery. 1991 Apr;28(4):496-501 [1851971.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4694-700 [9788624.001]
  • [Cites] Nat Genet. 1997 Apr;15(4):356-62 [9090379.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1063-71 [12569607.001]
  • [Cites] Proteomics. 2005 Mar;5(4):1167-77 [15759318.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1063-8 [11844831.001]
  • [Cites] Neurosurgery. 1992 Oct;31(4):636-42; discussion 642 [1407448.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] CA Cancer J Clin. 1990 Jan-Feb;40(1):9-26 [2104569.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jan;55(1):81-7 [8558174.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1260-7 [8651304.001]
  • [Cites] Science. 1997 Mar 28;275(5308):1943-7 [9072974.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10 (6):1871-4 [15041700.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Aug;26(4):319-31 [10931365.001]
  • [Cites] Neuroradiology. 1997 May;39(5):348-50 [9189880.001]
  • [Cites] Neuro Oncol. 2005 Oct;7(4):436-51 [16212809.001]
  • [Cites] Neurosurgery. 2004 Feb;54(2):349-57; discussion 357 [14744281.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Oncogene. 1995 Jun 1;10(11):2243-6 [7784070.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Jun;13(2):86-93 [7542911.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):779-86 [11549567.001]
  • [Cites] J Natl Cancer Inst. 2005 Jun 1;97(11):823-35 [15928303.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):233-47 [16612574.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):249-58 [15671553.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):203-15 [12187956.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Mar;21(3):195-206 [9523194.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):983-94 [8806688.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2775-83 [16284993.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):275-83 [15332332.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Nov-Dec;26(10):2466-74 [16286386.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • (PMID = 17001519.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 55
  •  go-up   go-down


76. Comincini S, Ferrara V, Arias A, Malovini A, Azzalin A, Ferretti L, Benericetti E, Cardarelli M, Gerosa M, Passarin MG, Turazzi S, Bellazzi R: Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy. Oncol Rep; 2007 May;17(5):989-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of PRND gene expression profiles in astrocytomas: relationship to tumor grades of malignancy.
  • It is abundant in testis and, unlike PRNP, it is expressed at low levels in the adult central nervous system (CNS).
  • Recently, ectopic expression of doppel was found in two different tumor types, specifically in glial and haematological cancers.
  • In order to address clinical important issues, PRND mRNA expression was investigated in a panel of 111 astrocytoma tissue samples, histologically classified according to the World Health Organization (WHO) criteria (6 grade I pilocytic astrocytomas, 15 grade II low-grade astrocytomas, 26 grade III anaplastic astrocytomas and 64 grade IV glioblastoma multiforme).
  • Real-time PRND gene expression profiling, after normalisation with GAPDH, revealed large differences between low (WHO I and II) and high grade (III and IV) of malignancy (P<0.001).
  • Extensive differences in PRND gene expression were also found within each grade of malignancy, suggesting that PRND mRNA quantitation might be useful to distinguish astrocytoma subtypes, and important in disease stratification and in the assessment of specific treatment strategies.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Prions / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Algorithms. Child. Cluster Analysis. Female. GPI-Linked Proteins. Gene Expression Profiling. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390034.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / PRND protein, human; 0 / Prions
  •  go-up   go-down


77. Hlobilkova A, Ehrmann J, Sedlakova E, Krejci V, Knizetova P, Fiuraskova M, Kala M, Kalita O, Kolar Z: Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression? Neoplasma; 2007;54(4):334-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
  • The aim of our study was to detect changes in expression of the following proteins: the tumor suppressors PTEN, p53, and p21Waf1/Cip1, glial fibrillary acidic protein (GFAP, as a marker of astroglial differentiation), the phosphorylated form of protein kinase B/Akt (PKB/Akt), which is downstream to the epidermal growth factor receptor (EGFR), and MDM2, which degrades p53.
  • Paraffin-embedded astrocytoma tissue samples from 89 patients were divided into low grade (grade I-II; 42 samples) and high grade astrocytomas (grade III-IV; 47 samples).
  • EGFR protein was detected in 29 % of low grade and in 60 % of high grade astrocytomas.
  • The expression of phosphorylated PKB/Akt was found in roughly the same proportions: in 86% of low grade and in 79% of high grade astrocytomas.
  • PTEN was not found in most of astrocytomas, 64% of low grade and 74% of high grade tumors showed no PTEN staining.
  • GFAP expression was decreased in tumor astrocytes compared to normal astrocytes and this decreased with grading.
  • GFAP positive tumor cells were detected in only 50% of low grade, and 32% of high grade astrocytomas.
  • Loss of p21Waf1/Cip1 expression was shown in 20% of low and in 45% of high grade tumors.
  • In the subgroup of high grade tumors with wild type p53, 86% showed p21Waf1/Cip1 expression, whereas in the subgroup of high grade tumors with altered p53, only 35% displayed p21Waf1/Cip1.
  • We conclude that EGFR expression increases with astrocytoma grading.
  • PTEN defects may also participate in aggressive tumor behaviour through activation of the PKB/Akt pathway.
  • EGFR is one of the factors, which drives the progression of astrocytomas from low to high grade stage.
  • [MeSH-major] Astrocytoma / metabolism. Cell Cycle. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Male. Middle Aged. Mutation / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. PTEN Phosphohydrolase / metabolism. Phosphorylation. Proto-Oncogene Proteins c-mdm2 / metabolism. Receptor, Epidermal Growth Factor / metabolism. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822324.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


78. Shen CF, Yuan XR, Qin ZQ: [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Oct;32(5):836-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of the expression of the RCAS1 mRNA and protein in astrocytic tumors].
  • OBJECTIVE: To determine the mRNA and protein expressions of RCAS1 in human astrocytic tumors, and to explore the relation between their expression and the genesis and development of tumor.
  • METHODS: The RCAS1 mRNA expression in human astrocytic tumors was evaluated by RT-PCR, and the RCAS1 protein expression was studied by immunohistochemical staining.
  • RESULTS: The quantities of RCAS1 mRNA expression between diffusive astrocytoma(Grade II) and anaplastic astrocytoma(Grade III), anaplastic astrocytoma and glioblastoma(Grade IV) were significantly different(P<0.05), while the expression scores of RCAS1 protein were different only between the anaplastic astrocytoma and glioblastoma(P<0.01).
  • RCAS1 protein expression was positively correlated with the tumor grade (r=0.573,P<0.001).
  • CONCLUSION: The RCAS1 expression is related to the histological grade of astrocytic tumor.
  • In astrocytic tumors, the RCAS1 expression is regulated transcriptionally and posttranscriptionally.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Astrocytoma / metabolism. Brain Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. RNA, Messenger / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18007080.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


79. Hwang SL, Lin CL, Lieu AS, Hwang YF, Howng SL, Hong YR, Chang DS, Lee KS: The expression of thyroid hormone receptor isoforms in human astrocytomas. Surg Neurol; 2008 Dec;70 Suppl 1:S1:4-8; discussion S1:8
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In this study, RT-PCR was used to examine the expression of human TR isoforms in 34 human astrocytoma samples.
  • RESULTS: We compared the TR expression between low grade (WHO grade II) and high grade (WHO grade III and IV).
  • The frequency of TRalpha1 or TRalpha2 expression significantly decreased with the grade of malignancy (P=.005 and P=.043, respectively).
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Receptors, Thyroid Hormone / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aging / metabolism. Child. Female. Humans. Male. Middle Aged. RNA / biosynthesis. RNA / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sex Characteristics. Thyroid Hormone Receptors alpha / biosynthesis. Thyroid Hormone Receptors alpha / genetics. Thyroid Hormone Receptors beta / biosynthesis. Thyroid Hormone Receptors beta / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18617237.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Thyroid Hormone; 0 / Thyroid Hormone Receptors alpha; 0 / Thyroid Hormone Receptors beta; 63231-63-0 / RNA
  •  go-up   go-down


80. Liu J, Zheng S, Yu JK, Zhang JM, Chen Z: Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor. J Zhejiang Univ Sci B; 2005 Jan;6(1):4-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum protein fingerprinting coupled with artificial neural network distinguishes glioma from healthy population or brain benign tumor.
  • To screen and evaluate protein biomarkers for the detection of gliomas (Astrocytoma grade I-IV) from healthy individuals and gliomas from brain benign tumors by using surface enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF-MS) coupled with an artificial neural network (ANN) algorithm.
  • SELDI-TOF-MS protein fingerprinting of serum from 105 brain tumor patients and healthy individuals, included 28 patients with glioma (Astrocytoma I-IV), 37 patients with brain benign tumor, and 40 age-matched healthy individuals.
  • Two thirds of the total samples of every compared pair as training set were used to set up discriminating patterns, and one third of total samples of every compared pair as test set were used to cross-validate; simultaneously, discriminate-cluster analysis derived SPSS 10.0 software was used to compare Astrocytoma grade I-II with grade III-IV ones.
  • An accuracy of 95.7%, sensitivity of 88.9%, specificity of 100%, positive predictive value of 90% and negative predictive value of 100% were obtained in a blinded test set comparing gliomas patients with healthy individuals; an accuracy of 86.4%, sensitivity of 88.9%, specificity of 84.6%, positive predictive value of 90% and negative predictive value of 85.7% were obtained when patient's gliomas was compared with benign brain tumor.
  • Total accuracy of 85.7%, accuracy of grade I-II Astrocytoma was 86.7%, accuracy of III-IV Astrocytoma was 84.6% were obtained when grade I-II Astrocytoma was compared with grade III-IV ones (discriminant analysis).
  • [MeSH-major] Astrocytoma / blood. Astrocytoma / diagnosis. Biomarkers, Tumor / blood. Brain Neoplasms / blood. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Neoplasm Proteins / blood. Peptide Mapping / methods
  • [MeSH-minor] Adult. Aged. Algorithms. Artificial Intelligence. Female. Humans. Male. Middle Aged. Neural Networks (Computer). Protein Array Analysis / methods. Reproducibility of Results. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Pain. 2003 Apr;102(3):251-6 [12670666.001]
  • [Cites] Curr Med Chem. 2003 May;10(10):831-43 [12678686.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s [12743135.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):267-79 [12781425.001]
  • [Cites] Curr Pharm Biotechnol. 2004 Feb;5(1):45-67 [14965209.001]
  • [Cites] Curr Opin Biotechnol. 2004 Feb;15(1):24-30 [15102462.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Bioinformatics. 2002 Mar;18(3):395-404 [11934738.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2541-52 [12171882.001]
  • (PMID = 15593384.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1390751
  •  go-up   go-down


81. Ren ZP, Olofsson T, Qu M, Hesselager G, Soussi T, Kalimo H, Smits A, Nistér M: Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol; 2007 Oct;66(10):944-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
  • We investigated genetic heterogeneity of astrocytic gliomas using p53 gene mutations as a marker.
  • Different parts of morphologically heterogeneous astrocytic gliomas were microdissected, and direct DNA sequencing of p53 gene exons 5 through 8 was performed.
  • Thirty-five glioma samples and tumor-adjacent normal-appearing brain tissue from 11 patients were analyzed.
  • The mutations were present in grade II, III, and IV astrocytic glioma areas.
  • Both severe functionally dead mutants and mutants with remaining transcriptional activity could be observed in the same tumor.
  • Coexistence of p53 gene mutations and the locus of heterozygosity was common, at least in astrocytomas grade III and in glioblastomas, and also occurred in astrocytoma grade II areas.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, p53 / genetics
  • [MeSH-minor] Adult. Aged. DNA Primers. DNA, Neoplasm / genetics. Female. Gene Frequency. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Microdissection. Middle Aged. Mutation / genetics. Mutation / physiology. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917588.001).
  • [ISSN] 0022-3069
  • [Journal-full-title] Journal of neuropathology and experimental neurology
  • [ISO-abbreviation] J. Neuropathol. Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm
  •  go-up   go-down


82. Grujicic M, Vuckovic N, Vulekovic P, Novakovic B: The basic morphological characteristics of astrocytomas in Vojvodina in the period 2001-2006. J BUON; 2009 Oct-Dec;14(4):625-8
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this investigation was to register the age, sex, tumor localization, frequency and histological types of patients with astrocytomas.
  • Tumor histological studies were carried out in the Laboratory of the Centre for Pathology and Histology of the Clinical Centre of Vojvodina.
  • Grade III astrocytomas were most common (55.4%).
  • The frequency of hemorrhage and thrombosis showed a positive correlation with the histological grade of astrocytomas.
  • CONCLUSION: The typical patient with astrocytoma is a male of 50-59 years.
  • The tumor is grade III located in the right frontal region.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sex Factors. Yugoslavia

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148453.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


83. Aragão Mde F, Otaduy MC, Melo RV, Azevedo Filho HR, Victor EG, Silva JL, Araújo N, Leite Cda C, Valença MM: [Multivoxel spectroscopy with short echo time: choline/N-acetyl-aspartate ratio and the grading of cerebral astrocytomas]. Arq Neuropsiquiatr; 2007 Jun;65(2A):286-94
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The choline/N-acetyl-aspartate (Cho/NAA) ratio, obtained by the multivoxel spectroscopy with short echo time (TE), was evaluated, in the histological grading of the brain astrocytomas (grades I, II and III-IV) in comparison with the normal cerebral parenchyma.
  • A significant increase (p<0.05) in the average ratios of Cho/NAA was observed in the three astrocytoma groups studied in relation to normal tissue, having a tendency to increase with the increase in grading, without any statistic significance, which corresponded to: 0.53+/-0.24 in the control group, 1.19+/-0.49 in grade I, 1.58+/-0.65 in grade II and 5.13+/-8.12 in the high grade group (grades III-IV), with variation in the values encountered.
  • There was an increase in the Cho/NAA ratio in 4/5 (80%) in grade I, 5/6 (83%) in grade II and 10/20 (50%) in grades III and IV.
  • We conclude that multivoxel spectroscopy with short TE can be used in discriminating between normal parenchyma and neoplasm tissue.
  • However, not all neoplasm tissue studied presented an increase in Cho/NAA, especially in the group with higher grade of malignancy.
  • [MeSH-major] Aspartic Acid / metabolism. Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Choline / metabolism. Female. Glioblastoma / pathology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Prospective Studies. Protons. Sensitivity and Specificity. Time Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17607430.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Protons; 30KYC7MIAI / Aspartic Acid; N91BDP6H0X / Choline
  •  go-up   go-down


84. El-Rayes BF, Norton CS, Sakr W, Maciorowski Z, Smith D, Pietraszkiewicz H, Del Mar Alonso M, Ensley JF: Cellular DNA content parameters as prognostic indicators in human astrocytomas. J Neurooncol; 2005 Jan;71(2):85-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Clinical parameters such as grade, size and/or location of the tumor are good predictors of outcome in patients with astrocytoma.
  • METHODS: Following optimization and validation of methodology for evaluating cellular DNA content parameters (CDCP), tumor DNA ploidy and percent S phase fraction (SPF) were determined from 64 patients using formalin fixed, paraffin embedded specimens (mean coefficient of variation=4.94) obtained over a 10-year period.
  • Median survival times correlated with grade (I/II=1154 vs. III/IV=483days, P=0.0317).
  • [MeSH-major] Astrocytoma / metabolism. Central Nervous System Neoplasms / metabolism. DNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Aneuploidy. Antineoplastic Agents / therapeutic use. Diploidy. Female. Flow Cytometry. Humans. Male. Middle Aged. Prognosis. Radiotherapy. S Phase. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1987 Jul 1;60(1):59-65 [2438028.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] Cytometry. 1985 Jul;6(4):327-33 [4017799.001]
  • [Cites] Cancer. 1999 Aug 15;86(4):672-83 [10440696.001]
  • [Cites] Clin Neuropathol. 1986 Jul-Aug;5(4):157-75 [3757347.001]
  • [Cites] Neuropathol Appl Neurobiol. 1989 Jul-Aug;15(4):331-8 [2779735.001]
  • [Cites] J Neurosurg. 1980 Aug;53(2):198-204 [7431058.001]
  • [Cites] Neurosurg Rev. 1988;11(2):177-87 [3244416.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):663-7 [2071227.001]
  • [Cites] Am J Clin Pathol. 1988 Sep;90(3):289-93 [2843034.001]
  • [Cites] J Neurosurg. 1994 May;80(5):877-83 [8169628.001]
  • [Cites] Cytometry. 1988 Jul;9(4):380-6 [2841078.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):195-204 [11859975.001]
  • [Cites] Pol J Pathol. 1997;48(1):31-6 [9200958.001]
  • [Cites] Cytometry. 1987 Sep;8(5):479-87 [2444398.001]
  • [Cites] Cell Tissue Kinet. 1982 May;15(3):235-49 [7083295.001]
  • [Cites] Folia Histochem Cytobiol. 2000;38(4):175-80 [11185722.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):13-21 [207834.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 May;16(5):1001-12 [7639120.001]
  • [Cites] Acta Neuropathol. 1979 Apr 12;46(1-2):39-44 [222110.001]
  • [Cites] J Neurosurg. 1994 Jan;80(1):85-9 [8271026.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1385-90 [10022821.001]
  • [Cites] J Pathol. 1994 Dec;174(4):275-82 [7884589.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):153-8 [9739018.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 15;75(2):77-89 [8055485.001]
  • [Cites] Cancer. 1985 Sep 1;56(5):1106-11 [2990664.001]
  • [Cites] Neurosurgery. 1994 Jul;35(1):119-25; discussion 125-6 [7936132.001]
  • [Cites] Cancer. 1994 Aug 1;74(3):920-7 [8039120.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):711-28 [3001488.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):379-84 [2536805.001]
  • [Cites] Cytometry. 1983 Mar;3(5):328-31 [6839881.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Dec;85(2):113-7 [8548733.001]
  • [Cites] J Neurooncol. 1997 Mar;32(1):7-17 [9049858.001]
  • [Cites] J Neuropathol Exp Neurol. 1990 Jan;49(1):71-8 [2153761.001]
  • [Cites] J Neurooncol. 1996 Oct;30(1):37-45 [8865001.001]
  • [Cites] Am J Clin Pathol. 1988 May;89(5):640-4 [2895977.001]
  • [Cites] Cytometry. 1987 Sep;8(5):488-93 [3665673.001]
  • [Cites] Cancer. 1992 Jul 15;70(2):538-46 [1319820.001]
  • (PMID = 15690121.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 40498-01A1; United States / NCI NIH HHS / CA / P30CA22453
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm
  •  go-up   go-down


85. Isolan GR, Ribas Filho JM, Isolan PM, Giovanini A, Malafaia O, Dini LI, Kummer A Jr, Negrão AW: [Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins]. Arq Neuropsiquiatr; 2005 Dec;63(4):997-1004
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Astrocytic neoplasms and correlation with mutate p53 and Ki-67 proteins].
  • The astrocytic neoplasms respond by 60% of the central nervous system tumors, being the study of the molecular biology an important step for the understanding of the genesis and biological behavior of these diseases.
  • The Ki-67 proteins, which are markers of the cellular proliferation, and p53, which is the product of the tumor suppressor gene TP53, are both important tumoral markers.
  • This study intends to identify and quantify the Ki-67 and p53 proteins in astrocytic tumors of different grades of malignancy, as well as to analyze their relations with age and gender.
  • Ki-67 and p53 proteins in 47 patients with surgically resected astrocytic neoplasms were studied through immunohistochemistry.
  • They have been previously classified and reviewed concerning their histological grade, as suggested by the World Health Organization.
  • p53 was present in 14 cases (35.13%) with a higher correlation with astrocytoma grade IV (p=0.59).
  • The hypotheses of a greater presence of Ki-67 and p53 in astrocytic neoplasms with a higher degree of malignancy, except for the correlation between grade III and p53, is corroborated by the results of this study.
  • [MeSH-major] Astrocytoma / chemistry. Central Nervous System Neoplasms / chemistry. Ki-67 Antigen / analysis. Tumor Suppressor Protein p53 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Immunohistochemistry. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400419.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


86. Lymbouridou R, Soufla G, Chatzinikola AM, Vakis A, Spandidos DA: Down-regulation of K-ras and H-ras in human brain gliomas. Eur J Cancer; 2009 May;45(7):1294-303
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated the mutational, mRNA and protein expression profile of the ras genes in 21 glioblastomas multiforme (grade IV), four fibrillary astrocytoma (grade II), four anaplastic astrocytoma (grade III) and 15 normal specimens.
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / mortality. Blotting, Western / methods. Case-Control Studies. Codon. Female. Gene Expression. Glioblastoma / genetics. Glioblastoma / metabolism. Glioblastoma / mortality. Humans. Male. Middle Aged. Oncogene Protein p21(ras) / analysis. Oncogene Protein p21(ras) / metabolism. Polymorphism, Restriction Fragment Length. Reverse Transcriptase Polymerase Chain Reaction / methods. Statistics, Nonparametric. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179066.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Codon; EC 3.6.5.2 / Oncogene Protein p21(ras)
  •  go-up   go-down


87. Bäcklund LM, Nilsson BR, Liu L, Ichimura K, Collins VP: Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer; 2005 Jul 11;93(1):124-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas.
  • Anaplastic astrocytoma (AA, WHO grade III) is, second to Glioblastoma, the most common and most malignant type of adult CNS tumour.
  • The survival data on 37 carefully sampled AA was correlated with the results of a detailed analysis of the status of nine genes known to be involved in the development of astrocytic tumours.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Genes, Retinoblastoma. Mutation
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Prognosis


88. Erdamar S, Bagci P, Oz B, Dirican A: Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors. J BUON; 2006 Apr-Jun;11(2):213-6
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of endothelial nitric oxide synthase and vascular endothelial growth factor expression with malignancy in patients with astrocytic tumors.
  • PURPOSE: Many characteristics of malignant brain tumors (increased vascular permeability, vasodilatation, neovascularisation and free radical injury to the tumor and adjacent normal tissues) are believed to be mediated by nitric oxide (NO) synthetized by endothelial NO synthase (eNOS).
  • Our aim was to study immunohistochemically the coexpression of eNOS and VEGF in astrocytic tumors and to analyse their possible correlation with tumor grade, angiogenesis and proliferation index.
  • MATERIALS AND METHODS: Sections from 120 randomly selected patients with supratentorial astrocytic tumors [38 glioblastomas (GB), 22 anaplastic astrocytomas (AA) and 20 low-grade astrocytomas (LA)], also including oligodendrogliomas (n=20) and mixed oligoastrocytomas (n=20), were immunostained with monoclonal antibodies for eNOS and VEGF using the avidin-biotin method.
  • The proliferative potential was assessed as the MIB-1 staining index for tumor cells.
  • RESULTS: There was positive correlation between eNOS and VEGF expressions and histological grade (p<0.05) in terms of intensity and extent of immunoreactivity distribution.
  • CONCLUSION: Overexpressions of eNOS and VEGF in astrocytic tumors were significantly correlated with histological grade, proliferative potential and malignant transformation.
  • The expression of VEGF in a necrotic and ischemic tumor such as GB is more intense and diffuse than low-grade astrocytomas.
  • These findings suggest that eNOS overexpression in tumor vasculature would be precipitated by transformation into an angiogenic phenotype in the process of neovascularisation in astrocytic tumors.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Nitric Oxide Synthase Type III / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Humans. Immunohistochemistry. Middle Aged. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318973.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  •  go-up   go-down


89. Yang WD, Wang ZG, Zhang Q, Pu PY, Yu Q, Yang SY, Zhang JN, Yue SY, Sun J: [Stereotactic resection of small intracerebral lesions in motor cortex using blood oxygen level depended functional magnetic resonance imaging and diffusion tensor imaging fusion guidance]. Zhonghua Yi Xue Za Zhi; 2008 Oct 28;88(39):2763-6
MedlinePlus Health Information. consumer health - Brain Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histological examination showed 3 cases of meningeoma, 3 cases of astrocytoma of grade II, 2 cases of astrocytoma of grade III, 2 cases of abscess, and 2 cases of cavernous angioma.
  • [MeSH-minor] Adolescent. Adult. Diffusion Magnetic Resonance Imaging. Female. Humans. Magnetic Resonance Angiography. Magnetic Resonance Imaging. Male. Middle Aged. Oximetry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080451.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


90. Klironomos G, Bravou V, Papachristou DJ, Gatzounis G, Varakis J, Parassi E, Repanti M, Papadaki H: Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas. Brain Pathol; 2010 Mar;20(2):490-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inhibitor of growth 4 (ING-4) is a tumor suppressor gene that interacts with nuclear factor-kappaB (NF-kappaB) and represses its transcriptional activity.
  • Several lines of evidence suggest that the tumor suppressor gene ING-4, the transcription factor NF-kappaB and its target genes matrix metalloproteases MMP-2, MMP-9 and urokinase plasminogen activator (u-PA) are critically involved in tumor invasion.
  • We found that ING-4 expression was significantly decreased in astrocytomas, and ING-4 loss was associated with tumor grade progression.
  • Expression of p65, a NF-kappaB subunit, was significantly higher in grade IV than in grade III and grade I/II tumors, and a statistical significant negative correlation between expression of ING-4 and expression of nuclear p65 was noticed.
  • Of note, astrocytomas of advanced histologic grades (grade III, IV) displayed significantly higher expression levels of these proteins compared to tumors of lower grades (grade I, II).
  • Collectively, our data suggest an essential role for ING-4 in human astrocytoma development and progression possibly through regulation of the NF-kappaB-dependent expression of genes involved in tumor invasion.
  • [MeSH-major] Astrocytoma / metabolism. Brain Neoplasms / metabolism. Cell Cycle Proteins / metabolism. Homeodomain Proteins / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / metabolism. Brain / pathology. Cell Nucleus / metabolism. Child. Cohort Studies. Disease Progression. Female. Humans. Male. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Middle Aged. NF-kappa B / metabolism. Urokinase-Type Plasminogen Activator / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775294.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Homeodomain Proteins; 0 / ING4 protein, human; 0 / NF-kappa B; 0 / Tumor Suppressor Proteins; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.24 / MMP2 protein, human; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


91. Perdiki M, Korkolopoulou P, Thymara I, Agrogiannis G, Piperi C, Boviatsis E, Kotsiakis X, Angelidakis D, Diamantopoulou K, Thomas-Tsagli E, Patsouris E: Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem; 2007 Jan;295(1-2):75-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we examined the expression of COX-2 in diffuse gliomas of astrocytic origin in relation to microvascular parameters, angiogenic factors and survival.
  • MATERIALS AND METHODS: A total of 83 cases of diffuse astrocytomas (grade II-IV) were analyzed by immunohistochemistry for the presence of COX-2.
  • RESULTS: COX-2 expression was detected in 79 cases (95%) with an increased expression in grade IV as compared to grades II/III (p=0.024).
  • Multivariate survival analysis showed that the interaction model of COX-2 with grade along with age were the only significant prognostic indicators.
  • CONCLUSION: These results implicate COX-2 in the angiogenesis and biological aggressiveness of diffuse astrocytomas, and suggest that it would be worthwhile to examine how the inhibition of COX-2 expression may influence astrocytoma patients' survival.
  • [MeSH-major] Angiogenesis Inducing Agents / metabolism. Astrocytoma / blood supply. Astrocytoma / enzymology. Cyclooxygenase 2 / metabolism. Glioma / blood supply. Glioma / enzymology. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Proportional Hazards Models. Survival Analysis. Vascular Endothelial Growth Factor A / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Chem. 1997 Jul;378(7):609-16 [9278140.001]
  • [Cites] Fundam Clin Pharmacol. 1996;10(1):1-17 [8900495.001]
  • [Cites] Ann Clin Lab Sci. 2001 Oct;31(4):325-48 [11688844.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] J Biol Chem. 1991 Jul 15;266(20):12866-72 [1712772.001]
  • [Cites] Cancer Res. 1999 Sep 1;59(17):4356-62 [10485483.001]
  • [Cites] Am J Pathol. 2000 Jul;157(1):29-35 [10880372.001]
  • [Cites] Ann Neurol. 1998 Jun;43(6):738-47 [9629843.001]
  • [Cites] Clin Cancer Res. 1997 Oct;3(10):1679-83 [9815550.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1505-8 [2493982.001]
  • [Cites] Int Urol Nephrol. 2005;37(1):47-53 [16132759.001]
  • [Cites] J Clin Invest. 2000 Jun;105(11):1589-94 [10841517.001]
  • [Cites] FASEB J. 1998 Sep;12(12):1063-73 [9737710.001]
  • [Cites] Neuropathology. 2004 Sep;24(3):201-7 [15484698.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):4064-8 [11051257.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2452-9 [9192825.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 1996 Sep;55(3):179-83 [8931116.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Feb;28(1):57-66 [11849564.001]
  • [Cites] Cancer Res. 1995 Apr 1;55(7):1464-72 [7882354.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1313-6 [8385741.001]
  • [Cites] Acta Neuropathol. 2001 Aug;102(2):181-7 [11563634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13926-31 [12242329.001]
  • [Cites] J Clin Pathol. 2006 Apr;59(4):382-6 [16467169.001]
  • [Cites] J Clin Invest. 1994 Feb;93(2):493-8 [8113389.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):10911-5 [10196169.001]
  • [Cites] Adv Prostaglandin Thromboxane Leukot Res. 1995;23:109-11 [7732812.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4375-81 [11389063.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Cancer Res. 2000 Sep 1;60(17):4926-31 [10987308.001]
  • [Cites] Cell. 1996 Nov 29;87(5):803-9 [8945508.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 21;90(20):1529-36 [9790545.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):362-72 [8625246.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1465-72 [14508834.001]
  • [Cites] Int J Cancer. 1994 Nov 15;59(4):520-9 [7525492.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5040-4 [11016626.001]
  • [Cites] J Neurosurg. 1999 Jan;90(1):72-7 [10413158.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:551-78 [10611972.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):267-78 [15175080.001]
  • [Cites] J Neurosurg Sci. 1989 Jan-Mar;33(1):65-9 [2674360.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1021-31; discussion 1031 [16522350.001]
  • [Cites] Nature. 1992 Feb 27;355(6363):846-7 [1311419.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1593-6 [1669840.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4566-9 [8840961.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2513-20 [10873107.001]
  • [Cites] Pathobiology. 2005;72(5):241-9 [16374068.001]
  • (PMID = 16868662.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Ki-67 Antigen; 0 / Membrane Proteins; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


92. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C: Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol; 2010 Aug;120(2):261-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current WHO classification of brain tumors defines gliomatosis cerebri (GC) as an extensively infiltrating astrocytic glioma involving at least three cerebral lobes.
  • Due to malignant biological behavior, GC is allotted to WHO grade III.
  • Recent reports showed IDH1 mutations in astrocytic and oligodendroglial tumors WHO grades II and III and in secondary glioblastomas with a frequency of up to 90%, whereas IDH1 mutations occurred in only 5% of primary glioblastomas.
  • We identified IDH1 mutations in 10/24 (42%) cases, which also included a solid tumor portion (type 2 GC), but not in 11 "classical" cases without solid tumor mass (type 1 GC).
  • Our data suggest that GC consists of two histological/molecular subtypes, type 1 being clearly distinct from diffuse astrocytoma, and type 2 sharing features with diffuse astrocytoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arginine / genetics. Astrocytoma / secondary. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Female. Histidine / genetics. Humans. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Oligodendroglioma / secondary. Polymorphism, Single Nucleotide / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


93. Combs SE, Schulz-Ertner D, Thilmann C, Edler L, Debus J: Fractionated stereotactic radiation therapy in the management of primary oligodendroglioma and oligoastrocytoma. Int J Radiat Oncol Biol Phys; 2005 Jul 1;62(3):797-802
Genetic Alliance. consumer health - Oligodendroglioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: We retrospectively reviewed 56 adult patients with supratentorial oligodendroglioma or oligoastrocytoma treated at our institution from January 1990 to December 2003 with fractionated stereotactic RT (FSRT).
  • With regard to histology, overall survival rates in the World Health Organization (WHO) Grade II group were 89% and 74% at 5 and 10 years, respectively.
  • In patients with WHO Grade III tumors, overall survival rates at 5 and 10 years were 69% and 46%, respectively.
  • In FSRT, the tumor volume can be irradiated with high doses, sparing volume of normal brain tissue.
  • [MeSH-major] Astrocytoma / surgery. Oligodendroglioma / surgery. Stereotaxic Techniques. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Dose Fractionation. Female. Humans. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936562.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Seo HS, Kim JH, Lee DH, Lee YH, Suh SI, Kim SY, Na DG: Nonenhancing intramedullary astrocytomas and other MR imaging features: a retrospective study and systematic review. AJNR Am J Neuroradiol; 2010 Mar;31(3):498-503
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Most intramedullary astrocytomas have been known to exhibit at least some enhancement on MR imaging regardless of cell type or tumor grade.
  • MATERIALS AND METHODS: A total of 19 consecutive patients (male to female ratio, 11:8; mean age, 27.84 +/- 19.0 years) with primary intramedullary astrocytomas (3 WHO grade I, 13 WHO grade II, 3 WHO grade III) who underwent preoperative MR imaging with contrast enhancement were included in this retrospective study from 4 institutions.
  • The tumor-enhancement patterns were classified into the following categories:.
  • RESULTS: In the retrospective study, 6 astrocytomas (32%), including 2 anaplastic astrocytomas, did not enhance at all.
  • In the literature review, the frequency of nonenhancing intramedullary astrocytomas was 14 of 76 (18%), including 2 anaplastic astrocytomas.
  • Therefore, astrocytoma must remain in the differential diagnosis of nonenhancing intramedullary lesions, particularly if the lesion demonstrates a prominent mass effect or cord expansion.
  • [MeSH-major] Astrocytoma / pathology. Magnetic Resonance Imaging / methods. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Male. Retrospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875469.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  • [Number-of-references] 21
  •  go-up   go-down


95. Ruban D, Byrne RW, Kanner A, Smith M, Cochran EJ, Roh D, Whisler WW: Chronic epilepsy associated with temporal tumors: long-term surgical outcome. Neurosurg Focus; 2009 Aug;27(2):E6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Thirty-eight patients were identified, all with low-grade tumors.
  • Gangliogliomas were the most common (36.8%), followed in descending order by dysembryoplastic neuroepithelial tumors (26.3%) and low-grade diffuse astrocytoma (10.5%).
  • The mean follow-up duration was 7.7 years (range 1.0-23.1 years), with 78.9% of patients having seizure status that improved to Engel Class I, 15.8% to Engel Class II, and 5.3% to Engel Class III.
  • [MeSH-minor] Adolescent. Adult. Amygdala / pathology. Amygdala / surgery. Astrocytoma / pathology. Astrocytoma / surgery. Child. Chronic Disease. Female. Ganglioglioma / pathology. Ganglioglioma / surgery. Glioma / pathology. Glioma / surgery. Hippocampus / pathology. Humans. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neurosurgical Procedures. Preoperative Care. Treatment Outcome


96. Hattingen E, Franz K, Pilatus U, Weidauer S, Lanfermann H: Postictal spectroscopy and imaging findings mimicking brain tumor recurrence. J Magn Reson Imaging; 2006 Jul;24(1):226-30
MedlinePlus Health Information. consumer health - Seizures.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postictal spectroscopy and imaging findings mimicking brain tumor recurrence.
  • (1)H magnetic resonance spectroscopic imaging (MRSI) was performed on a patient with an admission diagnosis of recurrent astrocytoma.
  • The patient had undergone surgical resection and radiation therapy for a left occipital astrocytoma WHO grade III 12 years previously, and presented with aphasia, right-sided hemiparesis, and severe headache.
  • The spectroscopic data were consistent with tumor recurrence.
  • However, the pattern of contrast enhancement on magnetic resonance imaging (MRI), evidence of an epileptic focus on electroencephalography (EEG), and spontaneous regression of the symptoms argued against tumor recurrence.
  • This is the first report of seizure-induced MRS abnormalities mimicking tumor recurrence.
  • [MeSH-minor] Adult. Aphasia / diagnosis. Aphasia / pathology. Astrocytoma / diagnosis. Astrocytoma / pathology. Contrast Media / pharmacology. Diagnosis, Differential. Electroencephalography / methods. Headache / pathology. Humans. Magnetic Resonance Imaging / methods. Paresis / diagnosis. Paresis / pathology. Recurrence

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16739121.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


97. Matsuyama Y, Sakai Y, Katayama Y, Imagama S, Ito Z, Wakao N, Sato K, Kamiya M, Yukawa Y, Kanemura T, Yanase M, Ishiguro N: Surgical results of intramedullary spinal cord tumor with spinal cord monitoring to guide extent of resection. J Neurosurg Spine; 2009 May;10(5):404-13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical results of intramedullary spinal cord tumor with spinal cord monitoring to guide extent of resection.
  • OBJECT: The authors investigated the outcome of intramedullary spinal cord tumor surgery, focusing on the effect of preoperative neurological status on postoperative mobility and the extent of tumor excision guided by intraoperative spinal cord monitoring prospectively.
  • METHODS: Intramedullary spinal cord tumor surgery was performed in 131 patients between 1997 and 2007.
  • A modified McCormick Scale (Grades I-V) was used to assess ambulatory ability (I = normal ambulation; II = mild motor sensory deficit, independent without external aid; III = independent with external aid; IV = care required; and V = wheelchair required).
  • The tumor types included astrocytoma (12 cases), ependymoma (46 cases), hemangioblastoma (16 cases), cavernous hemangioma (17 cases), and others (15 cases overall: gangliocytoma, 1; germ cell tumor, 1; lymphoma, 3; neurinoma, 1; meningioma, 1; oligodendroglioma, 1; sarcoidosis, 2; glioma, 1; and unknown, 4).
  • According to the preoperative McCormick Scale, ambulatory status was classified as Grades I, II, III, IV, and V in 41(38%), 30 (28%), 14 (13%), 19 (19%), and 2 (2%) patients, respectively.
  • The number of patients who did not lose ambulatory ability or who achieved an ambulatory status of Grade I or II postoperatively was 33 (80%), 21 (70%), 10 (71%), 8 (42%), and 1 (50%) in patients with preoperative Grades I, II, III, IV, and V, respectively.
  • Total excision was performed in 31 (79%) of 39 patients with preoperative Grade I, 12 (40%) of 30 patients with Grade II, 7 (50%) of 14 patients with Grade III, and 9 of 21 patients (38%) with Grade IV or V, indicating that the rate of total excision was significantly higher in patients with Grade I status.
  • Total excision in patients with Grade I or II ambulation was associated with a good prognosis for postoperative mobility.
  • However, the rate of postoperative deterioration was 31.5%, which is relatively high, and patients should be fully informed of this concern prior to intramedullary spinal cord tumor surgery.
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / surgery. Child. Ependymoma / surgery. Female. Follow-Up Studies. Hemangioblastoma / surgery. Hemangioma, Cavernous / surgery. Humans. Male. Middle Aged. Postoperative Complications. Prognosis. Prospective Studies. Walking

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19442001.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • Radiographic objective responses (partial responses) were observed in two patients with astrocytoma grade III and in one patient each with neuroblastoma and pleomorphic rhabdomyosarcoma, respectively.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


99. Maru SV, Holloway KA, Flynn G, Lancashire CL, Loughlin AJ, Male DK, Romero IA: Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation. J Neuroimmunol; 2008 Aug 13;199(1-2):35-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of chemokine receptors and chemokine production by adult human non-transformed astrocytes, grade III astrocytoma and grade IV glioblastoma tumour cell lines were determined.
  • Here, we show an increased expression of CXCR3 and CXCR4, and a decreased expression of CXCR1 and CCR4 by glioma cells compared to adult human astrocytes.
  • [MeSH-minor] Astrocytes / metabolism. Blotting, Western. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Enzyme-Linked Immunosorbent Assay. Extracellular Signal-Regulated MAP Kinases / metabolism. Flow Cytometry. Gene Expression. Humans. RNA, Messenger. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538864.001).
  • [ISSN] 0165-5728
  • [Journal-full-title] Journal of neuroimmunology
  • [ISO-abbreviation] J. Neuroimmunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / CXCL10 protein, human; 0 / Chemokine CXCL10; 0 / Chemokines; 0 / RNA, Messenger; 0 / Receptors, Chemokine; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


100. Cui W, Kong X, Cao HL, Wang X, Gao JF, Wu RL, Wang XC: [Mutations of p53 gene in 41 cases of human brain gliomas]. Ai Zheng; 2008 Jan;27(1):8-11
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mutation rate of p53 gene was significantly higher in grade III-IV gliomas than in grade I-II gliomas (P<0.01).
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Genes, p53 / genetics. Mutation, Missense. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Amino Acid Sequence. Base Sequence. Child. Exons. Female. Frameshift Mutation. Glioblastoma / genetics. Humans. Male. Middle Aged. Oligodendroglioma / genetics. Point Mutation. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18184456.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down






Advertisement